
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-8258669d.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-f4a99799.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="15253B498AF22DC3053B490010778B77.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="bmccanc">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="BMC Cancer">
<meta name="citation_title" content="Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers">
<meta name="citation_author" content="Ting Ouyang">
<meta name="citation_author_institution" content="Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China">
<meta name="citation_author" content="Fei Zhang">
<meta name="citation_author_institution" content="Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China">
<meta name="citation_author" content="Yan Yang">
<meta name="citation_author_institution" content="Department of Medical Management, Jinling Hospital, Medical School of Nanjing University, Nanjing, China">
<meta name="citation_author" content="Tianwei Luo">
<meta name="citation_author_institution" content="Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China">
<meta name="citation_author" content="Ao Chen">
<meta name="citation_author_institution" content="Department of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China">
<meta name="citation_author" content="Ning Han">
<meta name="citation_author_institution" content="Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China">
<meta name="citation_author" content="Jun Qian">
<meta name="citation_author_institution" content="Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China">
<meta name="citation_author" content="Xiaoyuan Chu">
<meta name="citation_author_institution" content="Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China">
<meta name="citation_author" content="Chao Chen">
<meta name="citation_author_institution" content="Department of Oncology, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China">
<meta name="citation_author" content="Mi Yang">
<meta name="citation_author_institution" content="Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China">
<meta name="citation_author_institution" content="The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000 China">
<meta name="citation_publication_date" content="2025 Aug 22">
<meta name="citation_volume" content="25">
<meta name="citation_firstpage" content="1353">
<meta name="citation_doi" content="10.1186/s12885-025-14559-1">
<meta name="citation_pmid" content="40841940">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/pdf/12885_2025_Article_14559.pdf">
<meta name="description" content="Lung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing ...">
<meta name="og:title" content="Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Lung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-header data-testid="header"    >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            <a class="ncbi-header__logo-container"
               href="https://www.ncbi.nlm.nih.gov/">
                <img alt="NCBI home page"
                     class="ncbi-header__logo-image"
                     src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg"
                     width="410"
                     height="100" />
            </a>

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                



    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true" >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                



    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true" data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="desktop-navigation-search-form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only" for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  action="https://www.ncbi.nlm.nih.gov/search/all/"
                  
                  autocomplete="off"
                  data-testid="mobile-navigation-search-form"
                  method="GET"
                  role="search">
                <label class="usa-sr-only" for="search-field-mobile-navigation">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="term" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
        

        
            Dashboard
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
        

        
            Publications
        

        
    </a>


                        </li>
                    
                        <li class="usa-nav__primary-item">
                            









    <a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
        

        
            Account settings
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12372320">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.1186/s12885-025-14559-1"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/12885_2025_Article_14559.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12372320%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12372320/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12372320/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-bmccanc.png" alt="BMC Cancer logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to BMC Cancer" title="Link to BMC Cancer" shape="default" href="https://doi.org/10.1186/s12885-025-14559-1" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">BMC Cancer</button></div>. 2025 Aug 22;25:1353. doi: <a href="https://doi.org/10.1186/s12885-025-14559-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.1186/s12885-025-14559-1</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22BMC%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22BMC%20Cancer%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22BMC%20Cancer%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22BMC%20Cancer%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Development and validation of a nomogram for predicting immunotherapy outcomes in lung cancer patients using clinical and blood biomarkers</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ouyang%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Ting Ouyang</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Ting Ouyang</span></h3>
<div class="p">
<sup>1</sup>Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Ouyang%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Ting Ouyang</span></a>
</div>
</div>
<sup>1,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20F%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Fei Zhang</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Fei Zhang</span></h3>
<div class="p">
<sup>2</sup>Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Zhang%20F%22%5BAuthor%5D" class="usa-link"><span class="name western">Fei Zhang</span></a>
</div>
</div>
<sup>2,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20Y%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Yan Yang</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Yan Yang</span></h3>
<div class="p">
<sup>3</sup>Department of Medical Management, Jinling Hospital, Medical School of Nanjing University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20Y%22%5BAuthor%5D" class="usa-link"><span class="name western">Yan Yang</span></a>
</div>
</div>
<sup>3,</sup><sup>#</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Luo%20T%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">Tianwei Luo</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">Tianwei Luo</span></h3>
<div class="p">
<sup>1</sup>Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Luo%20T%22%5BAuthor%5D" class="usa-link"><span class="name western">Tianwei Luo</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20A%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Ao Chen</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Ao Chen</span></h3>
<div class="p">
<sup>4</sup>Department of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20A%22%5BAuthor%5D" class="usa-link"><span class="name western">Ao Chen</span></a>
</div>
</div>
<sup>4</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20N%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">Ning Han</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">Ning Han</span></h3>
<div class="p">
<sup>5</sup>Department of Oncology,  Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Han%20N%22%5BAuthor%5D" class="usa-link"><span class="name western">Ning Han</span></a>
</div>
</div>
<sup>5</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qian%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id7"><span class="name western">Jun Qian</span></a><div hidden="hidden" id="id7">
<h3><span class="name western">Jun Qian</span></h3>
<div class="p">
<sup>6</sup>Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Qian%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jun Qian</span></a>
</div>
</div>
<sup>6</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20X%22%5BAuthor%5D" class="usa-link" aria-describedby="id8"><span class="name western">Xiaoyuan Chu</span></a><div hidden="hidden" id="id8">
<h3><span class="name western">Xiaoyuan Chu</span></h3>
<div class="p">
<sup>5</sup>Department of Oncology,  Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chu%20X%22%5BAuthor%5D" class="usa-link"><span class="name western">Xiaoyuan Chu</span></a>
</div>
</div>
<sup>5,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20C%22%5BAuthor%5D" class="usa-link" aria-describedby="id9"><span class="name western">Chao Chen</span></a><div hidden="hidden" id="id9">
<h3><span class="name western">Chao Chen</span></h3>
<div class="p">
<sup>5</sup>Department of Oncology,  Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chen%20C%22%5BAuthor%5D" class="usa-link"><span class="name western">Chao Chen</span></a>
</div>
</div>
<sup>5,</sup><sup>✉</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20M%22%5BAuthor%5D" class="usa-link" aria-describedby="id10"><span class="name western">Mi Yang</span></a><div hidden="hidden" id="id10">
<h3><span class="name western">Mi Yang</span></h3>
<div class="p">
<sup>1</sup>Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China </div>
<div class="p">
<sup>7</sup>The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000 China </div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Yang%20M%22%5BAuthor%5D" class="usa-link"><span class="name western">Mi Yang</span></a>
</div>
</div>
<sup>1,</sup><sup>7,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="Aff1">
<sup>1</sup>Department of Oncology, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College, Nanjing University of Chinese Medicine, Nanjing, China </div>
<div id="Aff2">
<sup>2</sup>Department of Clinical Laboratory, Jinling Hospital, Medical School of Nanjing University, Nanjing, China </div>
<div id="Aff3">
<sup>3</sup>Department of Medical Management, Jinling Hospital, Medical School of Nanjing University, Nanjing, China </div>
<div id="Aff4">
<sup>4</sup>Department of Oncology, Jinling Hospital, Nanjing Medical University, Nanjing, China </div>
<div id="Aff5">
<sup>5</sup>Department of Oncology,  Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, 210000 China </div>
<div id="Aff6">
<sup>6</sup>Department of Oncology, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China </div>
<div id="Aff7">
<sup>7</sup>The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing, 210000 China </div>
<div class="author-notes p">
<div class="fn" id="_fncrsp93pmc__">
<sup>✉</sup><p class="display-inline">Corresponding author.</p>
</div>
<div class="fn" id="_eqcntrb93pmc__">
<sup>#</sup><p class="display-inline">Contributed equally.</p>
</div>
</div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 Feb 13; Accepted 2025 Jun 20; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<div>© The Author(s) 2025</div>
<p><strong>Open Access</strong> This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">http://creativecommons.org/licenses/by/4.0/</a>.</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12372320  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40841940/" class="usa-link">40841940</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="Abs1"><h2>Abstract</h2>
<section id="sec1"><h3 class="pmc_sec_title">Background</h3>
<p id="Par1">Lung cancer remains the leading cause of cancer-related mortality worldwide. While immune checkpoint inhibitors (ICIs) have improved survival outcomes for some patients, their efficacy and adverse effects vary significantly. Thus, developing accurate and practical prognostic tools is essential to optimize treatment decision-making.</p></section><section id="sec2"><h3 class="pmc_sec_title">Methods</h3>
<p id="Par2">This retrospective study analyzed 436 lung cancer patients treated with ICIs, who were randomly divided into training (70%) and validation (30%) cohorts. Independent prognostic factors for overall survival (OS) and progression-free survival (PFS) were identified using LASSO regression and multivariate Cox regression. Nomograms were constructed based on clinical and blood biomarkers. Model performance was assessed using the concordance index (C-index), ROC curve, calibration curve, and decision curve analysis (DCA). Kaplan–Meier analysis validated patient stratification.</p></section><section id="sec3"><h3 class="pmc_sec_title">Results</h3>
<p id="Par3">The key independent predictive factors for OS and PFS included neutrophil-to-lymphocyte ratio (NLR), previous surgery, liver metastasis, clinical stage, treatment lines, and treatment response evaluation. The nomograms achieved C-index values of 0.709 (OS) and 0.730 (PFS) in the training cohort, with validation C-indexes of 0.655 (OS) and 0.694 (PFS). The ROC curves demonstrated good predictive accuracy for 12-, 24-, and 36-month outcomes. High-risk patients exhibited significantly shorter median OS and PFS (<em>P</em> &lt; 0.001).</p></section><section id="sec4"><h3 class="pmc_sec_title">Conclusion</h3>
<p id="Par4">The nomograms developed in this study, integrating clinical and blood biomarkers, provide a cost-effective, simple, and accurate tool for predicting the prognosis of lung cancer patients receiving ICIs treatment, to facilitate personalized clinical decision-making.</p></section><section id="kwd-group1" lang="en" class="kwd-group"><p><strong>Keywords:</strong> Lung cancer, Immune checkpoint inhibitors, Prognostic biomarkers, Nomogram</p></section></section><section id="Sec1"><h2 class="pmc_sec_title">Background</h2>
<p id="Par26">Lung cancer, a major malignancy, poses a significant threat to human health and is responsible for the highest rates of illness and death worldwide [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. In 2022, the Global Cancer Epidemiology Statistics (GLOBOCAN) estimated approximately 20 million new cases of lung cancer worldwide, resulting in about 9.7 million deaths [<a href="#CR1" class="usa-link" aria-describedby="CR1">1</a>]. According to the National Cancer Center, approximately 1.06 million new lung cancer cases and 733,300 deaths were reported in China, establishing it as the country's most deadly malignancy [<a href="#CR2" class="usa-link" aria-describedby="CR2">2</a>]. Immune checkpoint inhibitors (ICIs) targeting PD-(L)1 have emerged as a cornerstone therapy for patients lacking other targeted options [<a href="#CR3" class="usa-link" aria-describedby="CR3">3</a>–<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>]. However, response rates vary significantly, with only a subset of patients deriving long-term benefits [<a href="#CR5" class="usa-link" aria-describedby="CR5">5</a>–<a href="#CR7" class="usa-link" aria-describedby="CR7">7</a>]. Identifying reliable predictive biomarkers is essential to distinguish responders from non-responders and guide treatment decisions.</p>
<p id="Par27">In lung cancer, molecular indicators such as tumor PD-L1 expression, tumor mutational burden (TMB), microsatellite instability (MSI), and the presence of tumor-infiltrating immune cells are utilized to assess susceptibility to PD-(L)1 inhibitors [<a href="#CR8" class="usa-link" aria-describedby="CR8">8</a>–<a href="#CR10" class="usa-link" aria-describedby="CR10">10</a>]. These markers collectively inform the immune landscape of a tumor and help predict therapeutic responses. However, these markers inadequately capture the full variability in outcomes, likely due to the complex nature of the immune response to cancer [<a href="#CR11" class="usa-link" aria-describedby="CR11">11</a>, <a href="#CR12" class="usa-link" aria-describedby="CR12">12</a>].</p>
<p id="Par28">The tumor microenvironment (TME) plays a pivotal role in modulating immune responses to ICIs. Components of the TME, including immune cell infiltration, cytokine profiles, and stromal composition, critically influence immunotherapy efficacy. For instance, immunosuppressive elements such as regulatory T cells (Tregs) and myeloid-derived suppressor cells (MDSCs) within the TME can attenuate anti-tumor immunity, while high CD8 + T cell infiltration correlates with improved outcomes [<a href="#CR13" class="usa-link" aria-describedby="CR13">13</a>–<a href="#CR15" class="usa-link" aria-describedby="CR15">15</a>]. Recent studies emphasize the dynamic interplay between TME heterogeneity and ICI responsiveness. For example, spatial transcriptomic analyses reveal that immune-excluded or desert TME phenotypes are associated with resistance to PD-1 inhibitors [<a href="#CR16" class="usa-link" aria-describedby="CR16">16</a>]. Additionally, metabolic reprogramming within the TME, such as lactate accumulation from aerobic glycolysis, may impair T cell function and reduce therapeutic efficacy [<a href="#CR17" class="usa-link" aria-describedby="CR17">17</a>]. These findings underscore the need to integrate TME characteristics into prognostic models to refine patient stratification.</p>
<p id="Par29">In clinical practice, PD-L1 expression remains the most widely used biomarker for predicting the efficacy of immunotherapy. However, studies have shown only a weak correlation between PD-L1 expression levels in tumor biopsies and the overall response rate (ORR) to ICIs [<a href="#CR18" class="usa-link" aria-describedby="CR18">18</a>]. In lung cancer, evaluating factors such as smoking history, TMB, MSI, high expression of CTLA4, low expression of CX3CL1, and CD8 + T cell infiltration in the tumor microenvironment (TME) may provide more robust predictive capabilities for responses to anti-PD-1/PD-L1 therapies compared to histopathological PD-L1 quantification [<a href="#CR19" class="usa-link" aria-describedby="CR19">19</a>–<a href="#CR21" class="usa-link" aria-describedby="CR21">21</a>]. However, these markers have yet to be developed into a clinically robust and practical biomarker signature.</p>
<p id="Par30">Nomograms, graphical tools integrating multiple predictors, offer a practical solution for personalized prognosis estimation [<a href="#CR22" class="usa-link" aria-describedby="CR22">22</a>]. This study aims to develop and validate a nomogram combining clinical and biomarker data to predict outcomes in lung cancer patients prior to ICI initiation.</p></section><section id="Sec2"><h2 class="pmc_sec_title">Patients and methods</h2>
<section id="Sec3"><h3 class="pmc_sec_title">Patients</h3>
<p id="Par31">A total of 436 lung cancer patients treated with ICIs at Nanjing Jinling Hospital (January 2019–February 2024) were retrospectively analyzed. Patients were randomly allocated into training (70%) and validation (30%) cohorts.</p></section><section id="Sec4"><h3 class="pmc_sec_title">Inclusion and exclusion criteria</h3>
<p id="Par32">The inclusion criteria encompassed the following: (I) Patients aged ≥ 18 years with histologically confirmed lung cancer subtypes, including adenocarcinoma, squamous cell carcinoma, or small cell carcinoma; (II) Documented metastatic subtypes (e.g., liver, bone, or brain metastases) via imaging (CT/MRI) or biopsy; (III) Received ≥ 2 cycles of immune checkpoint inhibitors (ICIs). Patients with prior systemic therapies (chemotherapy, targeted therapy) were eligible if they met this criterion. Revised exclusion criteria were as follows: (I) Poor general condition (ECOG PS ≥ 3) or comorbidities (e.g., immune deficiencies) precluding tolerance to immunotherapy or chemotherapy; (II) Incomplete baseline biomarker data (NLR, PLR, CEA) or missing follow-up records; (III) Missing data &gt; 5% (e.g., CA125 in 8% of cases), which were addressed via multiple imputation by chained equations (MICE) under the missing-at-random assumption.</p></section><section id="Sec5"><h3 class="pmc_sec_title">Treatment regimens</h3>
<p id="Par33">The treatment regimens for ICIs included: 293 patients (67.2%) received combined chemotherapy; 57 patients (13.1%) were treated with both chemotherapy and anti-angiogenesis therapies (AATs); 54 patients (12.4%) received only AATs; and 32 patients (7.3%) underwent immune monotherapy.</p></section><section id="Sec6"><h3 class="pmc_sec_title">Data collection</h3>
<p id="Par34">Baseline characteristics collected from patients included age, sex, smoking history, metastatic sites at baseline, presence of ascites, prior treatments (surgery, radiotherapy, chemotherapy, targeted therapy, and anti-angiogenic therapy), site of disease progression, histological subtypes (adenocarcinoma, squamous cell carcinoma, small cell carcinoma, and others), gene mutations, cancer staging, types of ICIs administered, immunotherapy combination regimens, treatment lines, efficacy assessments, and immunotherapy. Additional factors such as treatment adverse reaction scores, ECOG PS, neutrophil/lymphocyte ratio (NLR), platelet/lymphocyte ratio (PLR), hemoglobin levels (HGB), carcinoembryonic antigen (CEA), carbohydrate antigen 125 (CA125) and 199 (CA199), white blood cell count (WBC), time to progression, date of death.</p></section><section id="Sec7"><h3 class="pmc_sec_title">Evaluation of curative effect</h3>
<p id="Par35">Imaging evaluations (CT/MRI) were performed at baseline, after every two treatment cycles, and at suspected progression. Scans were independently reviewed by two radiologists blinded to clinical outcomes, with discrepancies resolved by a third reviewer. Responses were categorized per RECIST 1.1: complete response (CR), partial response (PR), stable disease (SD), or progressive disease (PD) [<a href="#CR23" class="usa-link" aria-describedby="CR23">23</a>]. Target lesions were measured in axial planes, and non-target lesions were assessed qualitatively. Preliminary therapy response evaluations were conducted after two treatment cycles or as medically necessary. The primary objectives of the study were to determine overall survival (OS) and progression-free survival (PFS). OS was defined as the duration from the initiation of ICIs treatment to the last follow-up or death, whereas PFS was defined as the time from the initiation of ICIs treatment until disease progression. Patient safety was evaluated, with the severity of adverse events categorized according to the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. Informed consent was obtained from all participants in accordance with the ethical guidelines outlined in the Declaration of Helsinki (2013 revision), ensuring that all aspects of the study respected participant autonomy and safety.</p></section><section id="Sec8"><h3 class="pmc_sec_title">Biomarker detection</h3>
<p id="Par36">Peripheral blood samples were collected pre-treatment. NLR and PLR used the Mindray BC-6800Plus automated hematology analyzer (Mindray Corporation, Shenzhen, China), which was calibrated, controlled, and maintained according to the manufacturer's recommendations. CEA, CA125, and CA199 levels were quantified using Maglumi X8 fully automated chemiluminescence immunoassay analyzer (New Industry Biotech, Shenzhen, China). All assays followed manufacturer protocols, with inter- and intra-assay coefficients of variation &lt; 10%.</p></section><section id="Sec9"><h3 class="pmc_sec_title">Statistical analysis</h3>
<p id="Par37">Statistical analyses were conducted using R software (RRID:SCR_000432, version 4.1.3). Baseline characteristics were analyzed using Chi-square or Fisher's exact tests for categorical variables (reported as frequencies/proportions) and nonparametric tests (e.g., Mann–Whitney U) for non-normally distributed continuous variables (reported as medians with interquartile ranges). For variables with &gt; 5% missing data (e.g., CA125 in 8% of cases), multiple imputation by chained equations (MICE) with predictive mean matching was applied, generating five imputed datasets; pooled results were derived using Rubin's rules. Prognostic factors were identified via LASSO regression, with the optimal penalty parameter (λ) determined through tenfold cross-validation. Variables with non-zero coefficients were retained, and those statistically significant (<em>P</em> &lt; 0.05) in multivariate Cox regression were incorporated into the nomogram, presented as hazard ratios (HRs) with 95% confidence intervals (95%CIs). Multivariable models adjusted for confounders, including comorbidities (e.g., chronic obstructive pulmonary disease, diabetes), ECOG performance status, and combination therapies (chemotherapy/anti-angiogenic agents). Propensity score weighting (inverse probability of treatment weighting) was employed to balance baseline characteristics between treatment lines [<a href="#CR24" class="usa-link" aria-describedby="CR24">24</a>]. Model performance was evaluated using Harrell's concordance index (C-index), time-dependent ROC curves (AUC for 12-, 24-, and 36-month survival), and decision curve analysis (DCA) to assess clinical utility. Patients were stratified into low-risk and high-risk groups based on nomogram-derived thresholds. Survival differences were analyzed via Kaplan–Meier curves and log-rank tests, with statistical significance set at <em>P</em> &lt; 0.05.</p></section><section id="Sec10"><h3 class="pmc_sec_title">Ethical statement</h3>
<p id="Par38">The authors are responsible for all aspects of this work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. This study adhered to the ethical principles set forth in the Declaration of Helsinki (2013 revision) and received approval from the Ethics Committee of Nanjing Jinling Hospital (No. DZQH-KYLL-23-06). All participants provided informed consent.</p></section></section><section id="Sec11"><h2 class="pmc_sec_title">Result</h2>
<section id="Sec12"><h3 class="pmc_sec_title">Patient clinical characteristics</h3>
<p id="Par39">The study included a total of 436 patients, as depicted in the flowchart presented in Fig. <a href="#Fig1" class="usa-link">1</a>. These patients were assigned to either the training set (<em>n</em> = 306) and the validation set (<em>n</em> = 130). The age distribution revealed that 314 patients were younger than 70 years, while 122 patients were aged 70 years or older.The histological breakdown of the patient cohort showed that 209 patients (47.9%) had lung adenocarcinoma, 171 (39.2%) had squamous cell carcinoma, 38 (8.7%) had small cell lung cancer, and 18 (4.1%) had various other neoplasms. Prior treatments were as follows: 108 patients had surgery, 80 had radiation therapy, 215 had chemotherapy, 66 had targeted therapy, and 85 had antivascular therapy. Fluid accumulation prior to baseline assessment was observed in 30 patients (6.9%). PD-1 monoclonal antibody usage was: 137 patients received camrelizumab (31.4%), 23 received pembrolizumab (5.3%), 89 received sintilimab (20.4%), 144 received tislelizumab (33.0%), and 43 received other treatments (9.9%). Regarding treatment lines, 264 patients (60.6%) received first-line checkpoint inhibitors, 104 (23.9%) received second-line treatments, and 68 (15.6%) received third-line treatments. Comparative analyses indicated no significant statistical variances between the training and validation sets, confirming their comparability (<em>P</em> &gt; 0.05).</p>
<figure class="fig xbox font-sm" id="Fig1"><h4 class="obj_head">Fig. 1.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig1_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/59ee1f41c487/12885_2025_14559_Fig1_HTML.jpg" loading="lazy" id="MO1" height="572" width="709" alt="Fig. 1"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Flow chart of the study</p></figcaption></figure></section><section id="Sec13"><h3 class="pmc_sec_title">Selection of prognostic factors</h3>
<p id="Par40">LASSO Cox regression analysis was employed to evaluate recorded clinical measures, including clinicopathological characteristics and biomarkers, with the aim of identifying significant prognostic factors, as detailed in Table <a href="#Tab1" class="usa-link">1</a>. Significant correlations with OS were observed for smoking history, staging, surgery, radiotherapy, liver metastases, bone metastases, other metastases, ECOG PS, types of ICIs, immunotherapy regimens, treatment lines, efficacy assessment, AE grade, WBC, NLR, and CEA, as shown in Fig. <a href="#Fig2" class="usa-link">2</a>a-b. Significant correlations with PFS were found for ascites, lung metastases, liver metastases, bone metastases, lymph node metastases, other metastases, treatment lines, and efficacy assessment, as detailed in Fig. <a href="#Fig2" class="usa-link">2</a>c-d. Prospective prognostic factors for OS and PFS were identified by incorporating clinical indicators from LASSO Cox regression into multivariate Cox proportional hazards regression analysis. Multivariate Cox regression analysis was conducted to identify independent predictors of OS and PFS. Patients with an NLR &lt; 5.06, prior surgery, clinical stage II-III, fewer than two lines of therapy, SD and PR efficacy ratings, mild adverse events (grade 1/2), and no liver metastases experienced improved survival benefits. Similarly, patients with fewer than two lines of therapy, SD and PR efficacy assessments, and no initial ascites, lung, bone, lymph node, or other metastases demonstrated superior survival advantages, as shown in Table <a href="#Tab3" class="usa-link">3</a>.</p>
<section class="tw xbox font-sm" id="Tab1"><h4 class="obj_head">Table 1.</h4>
<div class="caption p"><p>Baseline characteristics</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Variables</th>
<th align="left" colspan="1" rowspan="1">Total (<em>n</em> = 436)</th>
<th align="left" colspan="1" rowspan="1">Training set (<em>n</em> = 306)</th>
<th align="left" colspan="1" rowspan="1">Validation set (<em>n</em> = 130)</th>
<th align="left" colspan="1" rowspan="1"><em>p</em></th>
</tr></thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1">Age</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.255</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 70</td>
<td align="left" colspan="1" rowspan="1">314 (72.02)</td>
<td align="left" colspan="1" rowspan="1">215 (70.26)</td>
<td align="left" colspan="1" rowspan="1">99 (76.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 70</td>
<td align="left" colspan="1" rowspan="1">122 (27.98)</td>
<td align="left" colspan="1" rowspan="1">91 (29.74)</td>
<td align="left" colspan="1" rowspan="1">31 (23.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CEA(ug/L)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.541</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 9.8</td>
<td align="left" colspan="1" rowspan="1">150 (34.40)</td>
<td align="left" colspan="1" rowspan="1">102 (33.33)</td>
<td align="left" colspan="1" rowspan="1">48 (36.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 9.8</td>
<td align="left" colspan="1" rowspan="1">286 (65.60)</td>
<td align="left" colspan="1" rowspan="1">204 (66.67)</td>
<td align="left" colspan="1" rowspan="1">82 (63.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA125(u/ml)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.925</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 35</td>
<td align="left" colspan="1" rowspan="1">91 (20.87)</td>
<td align="left" colspan="1" rowspan="1">63 (20.59)</td>
<td align="left" colspan="1" rowspan="1">28 (21.54)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 35</td>
<td align="left" colspan="1" rowspan="1">345 (79.13)</td>
<td align="left" colspan="1" rowspan="1">243 (79.41)</td>
<td align="left" colspan="1" rowspan="1">102 (78.46)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">CA199(u/ml)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.999</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 37</td>
<td align="left" colspan="1" rowspan="1">204 (46.79)</td>
<td align="left" colspan="1" rowspan="1">143 (46.73)</td>
<td align="left" colspan="1" rowspan="1">61 (46.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 37</td>
<td align="left" colspan="1" rowspan="1">232 (53.21)</td>
<td align="left" colspan="1" rowspan="1">163 (53.27)</td>
<td align="left" colspan="1" rowspan="1">69 (53.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">WBC((× 10<sup>9</sup>/L)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.999</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≥ 3.5</td>
<td align="left" colspan="1" rowspan="1">405 (92.89)</td>
<td align="left" colspan="1" rowspan="1">284 (92.81)</td>
<td align="left" colspan="1" rowspan="1">121 (93.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &lt; 3.5</td>
<td align="left" colspan="1" rowspan="1">31 (7.11)</td>
<td align="left" colspan="1" rowspan="1">22 (7.19)</td>
<td align="left" colspan="1" rowspan="1">9 (6.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">HGB(g/L)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.541</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≥ 115</td>
<td align="left" colspan="1" rowspan="1">286 (65.60)</td>
<td align="left" colspan="1" rowspan="1">204 (66.67)</td>
<td align="left" colspan="1" rowspan="1">82 (63.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &lt; 115</td>
<td align="left" colspan="1" rowspan="1">150 (34.40)</td>
<td align="left" colspan="1" rowspan="1">102 (33.33)</td>
<td align="left" colspan="1" rowspan="1">48 (36.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NEU_LYM</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.900</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 5.06</td>
<td align="left" colspan="1" rowspan="1">292 (66.97)</td>
<td align="left" colspan="1" rowspan="1">206 (67.32)</td>
<td align="left" colspan="1" rowspan="1">86 (66.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 5.06</td>
<td align="left" colspan="1" rowspan="1">144 (33.03)</td>
<td align="left" colspan="1" rowspan="1">100 (32.68)</td>
<td align="left" colspan="1" rowspan="1">44 (33.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">PLT_LYM</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.999</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 205.99</td>
<td align="left" colspan="1" rowspan="1">241 (55.28)</td>
<td align="left" colspan="1" rowspan="1">169 (55.23)</td>
<td align="left" colspan="1" rowspan="1">72 (55.38)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 205.99</td>
<td align="left" colspan="1" rowspan="1">195 (44.72)</td>
<td align="left" colspan="1" rowspan="1">137 (44.77)</td>
<td align="left" colspan="1" rowspan="1">58 (44.62)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Types of ICIs</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.378</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Carrilizumab</td>
<td align="left" colspan="1" rowspan="1">137 (31.42)</td>
<td align="left" colspan="1" rowspan="1">96 (31.37)</td>
<td align="left" colspan="1" rowspan="1">41 (31.54)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Pembrolizumab</td>
<td align="left" colspan="1" rowspan="1">23 (5.28)</td>
<td align="left" colspan="1" rowspan="1">15 (4.90)</td>
<td align="left" colspan="1" rowspan="1">8 (6.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Sindellizumab</td>
<td align="left" colspan="1" rowspan="1">89 (20.41)</td>
<td align="left" colspan="1" rowspan="1">66 (21.57)</td>
<td align="left" colspan="1" rowspan="1">23 (17.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Tirellizumab</td>
<td align="left" colspan="1" rowspan="1">144 (33.03)</td>
<td align="left" colspan="1" rowspan="1">104 (33.99)</td>
<td align="left" colspan="1" rowspan="1">40 (30.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">43 (9.86)</td>
<td align="left" colspan="1" rowspan="1">25 (8.17)</td>
<td align="left" colspan="1" rowspan="1">18 (13.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Gender</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.739</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Male</td>
<td align="left" colspan="1" rowspan="1">353 (80.96)</td>
<td align="left" colspan="1" rowspan="1">246 (80.39)</td>
<td align="left" colspan="1" rowspan="1">107 (82.31)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Female</td>
<td align="left" colspan="1" rowspan="1">83 (19.04)</td>
<td align="left" colspan="1" rowspan="1">60 (19.61)</td>
<td align="left" colspan="1" rowspan="1">23 (17.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Smoking history</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.663</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">206 (47.25)</td>
<td align="left" colspan="1" rowspan="1">142 (46.41)</td>
<td align="left" colspan="1" rowspan="1">64 (49.23)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">230 (52.75)</td>
<td align="left" colspan="1" rowspan="1">164 (53.59)</td>
<td align="left" colspan="1" rowspan="1">66 (50.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Surgery</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.753</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">328 (75.23)</td>
<td align="left" colspan="1" rowspan="1">232 (75.82)</td>
<td align="left" colspan="1" rowspan="1">96 (73.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">108 (24.77)</td>
<td align="left" colspan="1" rowspan="1">74 (24.18)</td>
<td align="left" colspan="1" rowspan="1">34 (26.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Radiotherapy(baseline)</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.999</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">356 (81.65)</td>
<td align="left" colspan="1" rowspan="1">250 (81.70)</td>
<td align="left" colspan="1" rowspan="1">106 (81.54)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">80 (18.35)</td>
<td align="left" colspan="1" rowspan="1">56 (18.30)</td>
<td align="left" colspan="1" rowspan="1">24 (18.46)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Chemotherapy</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.737</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">221 (50.69)</td>
<td align="left" colspan="1" rowspan="1">153 (50.00)</td>
<td align="left" colspan="1" rowspan="1">68 (52.31)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">215 (49.31)</td>
<td align="left" colspan="1" rowspan="1">153 (50.00)</td>
<td align="left" colspan="1" rowspan="1">62 (47.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Targeted therapy</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.595</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">370 (84.86)</td>
<td align="left" colspan="1" rowspan="1">262 (85.62)</td>
<td align="left" colspan="1" rowspan="1">108 (83.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">66 (15.14)</td>
<td align="left" colspan="1" rowspan="1">44 (14.38)</td>
<td align="left" colspan="1" rowspan="1">22 (16.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Antiangiogenic therapy</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.310</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">351 (80.50)</td>
<td align="left" colspan="1" rowspan="1">242 (79.08)</td>
<td align="left" colspan="1" rowspan="1">109 (83.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">85 (19.50)</td>
<td align="left" colspan="1" rowspan="1">64 (20.92)</td>
<td align="left" colspan="1" rowspan="1">21 (16.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Histological subtype</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.232</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Adenocarcinoma</td>
<td align="left" colspan="1" rowspan="1">209 (47.94)</td>
<td align="left" colspan="1" rowspan="1">156 (50.98)</td>
<td align="left" colspan="1" rowspan="1">53 (40.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Squamous cell carcinoma</td>
<td align="left" colspan="1" rowspan="1">171 (39.22)</td>
<td align="left" colspan="1" rowspan="1">115 (37.58)</td>
<td align="left" colspan="1" rowspan="1">56 (43.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Small cell lung cancer</td>
<td align="left" colspan="1" rowspan="1">38 (8.71)</td>
<td align="left" colspan="1" rowspan="1">24 (7.84)</td>
<td align="left" colspan="1" rowspan="1">14 (10.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">18 (4.13)</td>
<td align="left" colspan="1" rowspan="1">11 (3.59)</td>
<td align="left" colspan="1" rowspan="1">7 (5.38)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Stage</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.866</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> II-III</td>
<td align="left" colspan="1" rowspan="1">110 (25.23)</td>
<td align="left" colspan="1" rowspan="1">76 (24.84)</td>
<td align="left" colspan="1" rowspan="1">34 (26.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> IV</td>
<td align="left" colspan="1" rowspan="1">326 (74.77)</td>
<td align="left" colspan="1" rowspan="1">230 (75.16)</td>
<td align="left" colspan="1" rowspan="1">96 (73.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Genetic mutation</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.413</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">94 (21.56)</td>
<td align="left" colspan="1" rowspan="1">71 (23.20)</td>
<td align="left" colspan="1" rowspan="1">23 (17.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">58 (13.30)</td>
<td align="left" colspan="1" rowspan="1">41 (13.40)</td>
<td align="left" colspan="1" rowspan="1">17 (13.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Unknow</td>
<td align="left" colspan="1" rowspan="1">284 (65.14)</td>
<td align="left" colspan="1" rowspan="1">194 (63.40)</td>
<td align="left" colspan="1" rowspan="1">90 (69.23)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Treatment Plan</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.451</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + chemotherapy</td>
<td align="left" colspan="1" rowspan="1">293 (67.20)</td>
<td align="left" colspan="1" rowspan="1">202 (66.01)</td>
<td align="left" colspan="1" rowspan="1">91 (70.00)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + chemotherapy + AATs</td>
<td align="left" colspan="1" rowspan="1">57 (13.07)</td>
<td align="left" colspan="1" rowspan="1">39 (12.75)</td>
<td align="left" colspan="1" rowspan="1">18 (13.85)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + AATs</td>
<td align="left" colspan="1" rowspan="1">54 (12.39)</td>
<td align="left" colspan="1" rowspan="1">43 (14.05)</td>
<td align="left" colspan="1" rowspan="1">11 (8.46)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs</td>
<td align="left" colspan="1" rowspan="1">32 (7.34)</td>
<td align="left" colspan="1" rowspan="1">22 (7.19)</td>
<td align="left" colspan="1" rowspan="1">10 (7.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lines</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.858</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1</td>
<td align="left" colspan="1" rowspan="1">264 (60.55)</td>
<td align="left" colspan="1" rowspan="1">186 (60.78)</td>
<td align="left" colspan="1" rowspan="1">78 (60.00)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 2</td>
<td align="left" colspan="1" rowspan="1">104 (23.85)</td>
<td align="left" colspan="1" rowspan="1">71 (23.20)</td>
<td align="left" colspan="1" rowspan="1">33 (25.38)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 2</td>
<td align="left" colspan="1" rowspan="1">68 (15.60)</td>
<td align="left" colspan="1" rowspan="1">49 (16.01)</td>
<td align="left" colspan="1" rowspan="1">19 (14.62)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">ECOG PS</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.438</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0 ~ 1</td>
<td align="left" colspan="1" rowspan="1">379 (86.93)</td>
<td align="left" colspan="1" rowspan="1">263 (85.95)</td>
<td align="left" colspan="1" rowspan="1">116 (89.23)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 2</td>
<td align="left" colspan="1" rowspan="1">57 (13.07)</td>
<td align="left" colspan="1" rowspan="1">43 (14.05)</td>
<td align="left" colspan="1" rowspan="1">14 (10.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Efficacy assessment</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.502</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PD</td>
<td align="left" colspan="1" rowspan="1">116 (26.61)</td>
<td align="left" colspan="1" rowspan="1">82 (26.80)</td>
<td align="left" colspan="1" rowspan="1">34 (26.15)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> SD</td>
<td align="left" colspan="1" rowspan="1">261 (59.86)</td>
<td align="left" colspan="1" rowspan="1">179 (58.50)</td>
<td align="left" colspan="1" rowspan="1">82 (63.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PR</td>
<td align="left" colspan="1" rowspan="1">59 (13.53)</td>
<td align="left" colspan="1" rowspan="1">45 (14.71)</td>
<td align="left" colspan="1" rowspan="1">14 (10.77)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">AE grade</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.863</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0</td>
<td align="left" colspan="1" rowspan="1">209 (47.94)</td>
<td align="left" colspan="1" rowspan="1">147 (48.04)</td>
<td align="left" colspan="1" rowspan="1">62 (47.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1 ~ 2</td>
<td align="left" colspan="1" rowspan="1">182 (41.74)</td>
<td align="left" colspan="1" rowspan="1">126 (41.18)</td>
<td align="left" colspan="1" rowspan="1">56 (43.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 3 + </td>
<td align="left" colspan="1" rowspan="1">45 (10.32)</td>
<td align="left" colspan="1" rowspan="1">33 (10.78)</td>
<td align="left" colspan="1" rowspan="1">12 (9.23)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Ascites</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.818</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">406 (93.12)</td>
<td align="left" colspan="1" rowspan="1">286 (93.46)</td>
<td align="left" colspan="1" rowspan="1">120 (92.31)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">30 (6.88)</td>
<td align="left" colspan="1" rowspan="1">20 (6.54)</td>
<td align="left" colspan="1" rowspan="1">10 (7.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lung metastases</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.784</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">344 (78.90)</td>
<td align="left" colspan="1" rowspan="1">243 (79.41)</td>
<td align="left" colspan="1" rowspan="1">101 (77.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">92 (21.10)</td>
<td align="left" colspan="1" rowspan="1">63 (20.59)</td>
<td align="left" colspan="1" rowspan="1">29 (22.31)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Liver metastases</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.076</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">408 (93.58)</td>
<td align="left" colspan="1" rowspan="1">291 (95.10)</td>
<td align="left" colspan="1" rowspan="1">117 (90.00)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">28 (6.42)</td>
<td align="left" colspan="1" rowspan="1">15 (4.90)</td>
<td align="left" colspan="1" rowspan="1">13 (10.00)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Bone metastases</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.236</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">389 (89.22)</td>
<td align="left" colspan="1" rowspan="1">269 (87.91)</td>
<td align="left" colspan="1" rowspan="1">120 (92.31)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">47 (10.78)</td>
<td align="left" colspan="1" rowspan="1">37 (12.09)</td>
<td align="left" colspan="1" rowspan="1">10 (7.69)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Lymph node metastases</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.999</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">380 (87.16)</td>
<td align="left" colspan="1" rowspan="1">267 (87.25)</td>
<td align="left" colspan="1" rowspan="1">113 (86.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">56 (12.84)</td>
<td align="left" colspan="1" rowspan="1">39 (12.75)</td>
<td align="left" colspan="1" rowspan="1">17 (13.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Other metastases</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.831</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">373 (85.55)</td>
<td align="left" colspan="1" rowspan="1">263 (85.95)</td>
<td align="left" colspan="1" rowspan="1">110 (84.62)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">63 (14.45)</td>
<td align="left" colspan="1" rowspan="1">43 (14.05)</td>
<td align="left" colspan="1" rowspan="1">20 (15.38)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Radiotherapy</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1">0.563</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">302 (69.27)</td>
<td align="left" colspan="1" rowspan="1">215 (70.26)</td>
<td align="left" colspan="1" rowspan="1">87 (66.92)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">134 (30.73)</td>
<td align="left" colspan="1" rowspan="1">91 (29.74)</td>
<td align="left" colspan="1" rowspan="1">43 (33.08)</td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab1/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p22"><p><em>WBC</em> White blood cell count, <em>CEA</em> Carcinoembryonic antigen, <em>NEU_LYM</em> Neutrophil/lymphocyte ratio, <em>PLT_LYM</em> Platelet/lymphocyte ratio, <em>HGB</em> Hemoglobin, <em>CA125</em> Carbohydrate antigen 125, <em>CA199</em> Carbohydrate antigen 199, <em>AATs</em> Anti-angiogenesis therapies, <em>ECOG PS</em> Eastern Cooperative Oncology Group Performance Status, <em>AE</em> Adverse event, <em>PD</em> Progressive disease, <em>PR</em> Partial response, <em>SD</em> Stable disease</p></div></div></section><figure class="fig xbox font-sm" id="Fig2"><h4 class="obj_head">Fig. 2.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig2_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/1664569d4253/12885_2025_14559_Fig2_HTML.jpg" loading="lazy" id="MO2" height="679" width="778" alt="Fig. 2"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Factor selection and linear map development using clinicopathological characteristics and peripheral blood markers. <strong>a</strong> OS-LASSO coefficient profiles of candidate variables. <strong>c</strong> PFS-LASSO coefficient profiles of candidate variables. <strong>b</strong> and <strong>d</strong>, The LASSO study utilized ten-fold cross-validation to identify the ideal tuning parameter lamb λ. The non-zero coefficients established via ten-fold cross-validation are represented by the dashed and vertical lines. The initial vertical line corresponds to the smallest measured error. The second vertical line shows that the cross-validation error is within a standard error minimum</p></figcaption></figure><section class="tw xbox font-sm" id="Tab3"><h4 class="obj_head">Table 3.</h4>
<div class="caption p"><p>PFS multivariate cox hazards analysis</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Variables</th>
<th align="left" colspan="1" rowspan="1">HR</th>
<th align="left" colspan="1" rowspan="1">95%CI</th>
<th align="left" colspan="1" rowspan="1">P</th>
<th align="left" colspan="1" rowspan="1">Wald</th>
<th align="left" colspan="1" rowspan="1">B</th>
<th align="left" colspan="1" rowspan="1">SE</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="7" rowspan="1">Lines</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 2</td>
<td align="left" colspan="1" rowspan="1">0.967</td>
<td align="left" colspan="1" rowspan="1">0.694–1.347</td>
<td align="left" colspan="1" rowspan="1">0.842</td>
<td align="left" colspan="1" rowspan="1">0.039</td>
<td align="left" colspan="1" rowspan="1">−0.034</td>
<td align="left" colspan="1" rowspan="1">0.169</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 2</td>
<td align="left" colspan="1" rowspan="1">1.864</td>
<td align="left" colspan="1" rowspan="1">1.282–2.712</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">10.612</td>
<td align="left" colspan="1" rowspan="1">0.623</td>
<td align="left" colspan="1" rowspan="1">0.191</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Efficacy assessment</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PD</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> SD</td>
<td align="left" colspan="1" rowspan="1">0.368</td>
<td align="left" colspan="1" rowspan="1">0.267–0.508</td>
<td align="left" colspan="1" rowspan="1"> &lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">36.838</td>
<td align="left" colspan="1" rowspan="1">−0.999</td>
<td align="left" colspan="1" rowspan="1">0.165</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PR</td>
<td align="left" colspan="1" rowspan="1">0.380</td>
<td align="left" colspan="1" rowspan="1">0.233–0.620</td>
<td align="left" colspan="1" rowspan="1"> &lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">14.979</td>
<td align="left" colspan="1" rowspan="1">−0.968</td>
<td align="left" colspan="1" rowspan="1">0.250</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Ascites</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">2.200</td>
<td align="left" colspan="1" rowspan="1">1.368–3.537</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">10.576</td>
<td align="left" colspan="1" rowspan="1">0.788</td>
<td align="left" colspan="1" rowspan="1">0.242</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Lung metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.737</td>
<td align="left" colspan="1" rowspan="1">1.262–2.390</td>
<td align="left" colspan="1" rowspan="1">0.001</td>
<td align="left" colspan="1" rowspan="1">11.484</td>
<td align="left" colspan="1" rowspan="1">0.552</td>
<td align="left" colspan="1" rowspan="1">0.163</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Liver metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.260</td>
<td align="left" colspan="1" rowspan="1">0.757–2.098</td>
<td align="left" colspan="1" rowspan="1">0.374</td>
<td align="left" colspan="1" rowspan="1">0.790</td>
<td align="left" colspan="1" rowspan="1">0.231</td>
<td align="left" colspan="1" rowspan="1">0.260</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Bone metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.718</td>
<td align="left" colspan="1" rowspan="1">1.099–2.688</td>
<td align="left" colspan="1" rowspan="1">0.018</td>
<td align="left" colspan="1" rowspan="1">5.631</td>
<td align="left" colspan="1" rowspan="1">0.541</td>
<td align="left" colspan="1" rowspan="1">0.228</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Lymph node metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.587</td>
<td align="left" colspan="1" rowspan="1">1.089–2.313</td>
<td align="left" colspan="1" rowspan="1">0.016</td>
<td align="left" colspan="1" rowspan="1">5.786</td>
<td align="left" colspan="1" rowspan="1">0.462</td>
<td align="left" colspan="1" rowspan="1">0.192</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Other metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.493</td>
<td align="left" colspan="1" rowspan="1">1.064–2.093</td>
<td align="left" colspan="1" rowspan="1">0.020</td>
<td align="left" colspan="1" rowspan="1">5.388</td>
<td align="left" colspan="1" rowspan="1">0.400</td>
<td align="left" colspan="1" rowspan="1">0.173</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p28"><p><em>PD</em> Progressive disease, <em>PR</em> Partial response, <em>SD</em> Stable disease</p></div></div></section></section><section id="Sec14"><h3 class="pmc_sec_title">Build OS and PFS nomogram</h3>
<p id="Par41">Based on the multivariate Cox regression findings (Tables <a href="#Tab2" class="usa-link">2</a> and <a href="#Tab3" class="usa-link">3</a>), OS Prediction nomogram 1 was developed using NLR, surgery, staging, treatment lines, efficacy assessment, AE grade, and liver metastases. PFS Prediction nomogram 2 was constructed with variables such as ascites, lung, bone, lymph node, other metastases, treatment lines, and efficacy assessments. Patients were randomly allocated to the training set or the validation set in a 7:3 ratio. The training set was critical for constructing the prediction model, while the validation set was used for internal validation. Figure <a href="#Fig3" class="usa-link">3</a> shows nomograms forecasting OS and PFS at 12, 24, and 36 months.</p>
<section class="tw xbox font-sm" id="Tab2"><h4 class="obj_head">Table 2.</h4>
<div class="caption p"><p>OS multivariate cox hazards analysis</p></div>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th align="left" colspan="1" rowspan="1">Variables</th>
<th align="left" colspan="1" rowspan="1">HR</th>
<th align="left" colspan="1" rowspan="1">95%CI</th>
<th align="left" colspan="1" rowspan="1">P</th>
<th align="left" colspan="1" rowspan="1">Wald</th>
<th align="left" colspan="1" rowspan="1">B</th>
<th align="left" colspan="1" rowspan="1">SE</th>
</tr></thead>
<tbody>
<tr><td align="left" colspan="7" rowspan="1">CEA</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 9.8</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 9.8</td>
<td align="left" colspan="1" rowspan="1">0.704</td>
<td align="left" colspan="1" rowspan="1">0.487–1.018</td>
<td align="left" colspan="1" rowspan="1">0.062</td>
<td align="left" colspan="1" rowspan="1">3.486</td>
<td align="left" colspan="1" rowspan="1">−0.351</td>
<td align="left" colspan="1" rowspan="1">0.188</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">WBC</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≥ 3.5</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &lt; 3.5</td>
<td align="left" colspan="1" rowspan="1">1.326</td>
<td align="left" colspan="1" rowspan="1">0.706–2.493</td>
<td align="left" colspan="1" rowspan="1">0.38</td>
<td align="left" colspan="1" rowspan="1">0.769</td>
<td align="left" colspan="1" rowspan="1">0.282</td>
<td align="left" colspan="1" rowspan="1">0.322</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">NLR</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ≤ 5.06</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 5.06</td>
<td align="left" colspan="1" rowspan="1">1.538</td>
<td align="left" colspan="1" rowspan="1">1.045–2.263</td>
<td align="left" colspan="1" rowspan="1">0.029</td>
<td align="left" colspan="1" rowspan="1">4.772</td>
<td align="left" colspan="1" rowspan="1">0.430</td>
<td align="left" colspan="1" rowspan="1">0.197</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1">Types of ICIs</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Camrelizumab</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Pembrolizumab</td>
<td align="left" colspan="1" rowspan="1">1.756</td>
<td align="left" colspan="1" rowspan="1">0.789–3.909</td>
<td align="left" colspan="1" rowspan="1">0.168</td>
<td align="left" colspan="1" rowspan="1">1.905</td>
<td align="left" colspan="1" rowspan="1">0.563</td>
<td align="left" colspan="1" rowspan="1">0.408</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Sintilimab</td>
<td align="left" colspan="1" rowspan="1">0.654</td>
<td align="left" colspan="1" rowspan="1">0.400–1.067</td>
<td align="left" colspan="1" rowspan="1">0.089</td>
<td align="left" colspan="1" rowspan="1">2.887</td>
<td align="left" colspan="1" rowspan="1">−0.425</td>
<td align="left" colspan="1" rowspan="1">0.250</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Tislelizumab</td>
<td align="left" colspan="1" rowspan="1">1.236</td>
<td align="left" colspan="1" rowspan="1">0.785–1.947</td>
<td align="left" colspan="1" rowspan="1">0.360</td>
<td align="left" colspan="1" rowspan="1">0.837</td>
<td align="left" colspan="1" rowspan="1">0.212</td>
<td align="left" colspan="1" rowspan="1">0.232</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Other</td>
<td align="left" colspan="1" rowspan="1">1.344</td>
<td align="left" colspan="1" rowspan="1">0.701–2.578</td>
<td align="left" colspan="1" rowspan="1">0.373</td>
<td align="left" colspan="1" rowspan="1">0.792</td>
<td align="left" colspan="1" rowspan="1">0.296</td>
<td align="left" colspan="1" rowspan="1">0.332</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Smoking history</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.377</td>
<td align="left" colspan="1" rowspan="1">0.965–1.964</td>
<td align="left" colspan="1" rowspan="1">0.078</td>
<td align="left" colspan="1" rowspan="1">3.115</td>
<td align="left" colspan="1" rowspan="1">0.320</td>
<td align="left" colspan="1" rowspan="1">0.181</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Surgery</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">0.493</td>
<td align="left" colspan="1" rowspan="1">0.312–0.780</td>
<td align="left" colspan="1" rowspan="1">0.003</td>
<td align="left" colspan="1" rowspan="1">9.131</td>
<td align="left" colspan="1" rowspan="1">−0.707</td>
<td align="left" colspan="1" rowspan="1">0.234</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Radiotherapy(baseline)</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.388</td>
<td align="left" colspan="1" rowspan="1">0.855–2.254</td>
<td align="left" colspan="1" rowspan="1">0.185</td>
<td align="left" colspan="1" rowspan="1">1.755</td>
<td align="left" colspan="1" rowspan="1">0.328</td>
<td align="left" colspan="1" rowspan="1">0.247</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Staging</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> II-III</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> IV</td>
<td align="left" colspan="1" rowspan="1">1.781</td>
<td align="left" colspan="1" rowspan="1">1.124–2.822</td>
<td align="left" colspan="1" rowspan="1">0.014</td>
<td align="left" colspan="1" rowspan="1">6.030</td>
<td align="left" colspan="1" rowspan="1">0.577</td>
<td align="left" colspan="1" rowspan="1">0.235</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Treatment Plan</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + chemotherapy</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + chemotherapy + AATs</td>
<td align="left" colspan="1" rowspan="1">1.643</td>
<td align="left" colspan="1" rowspan="1">0.976–2.767</td>
<td align="left" colspan="1" rowspan="1">0.062</td>
<td align="left" colspan="1" rowspan="1">3.486</td>
<td align="left" colspan="1" rowspan="1">0.497</td>
<td align="left" colspan="1" rowspan="1">0.266</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs + AATs</td>
<td align="left" colspan="1" rowspan="1">0.746</td>
<td align="left" colspan="1" rowspan="1">0.439–1.269</td>
<td align="left" colspan="1" rowspan="1">0.280</td>
<td align="left" colspan="1" rowspan="1">1.166</td>
<td align="left" colspan="1" rowspan="1">−0.292</td>
<td align="left" colspan="1" rowspan="1">0.271</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> ICIs</td>
<td align="left" colspan="1" rowspan="1">0.477</td>
<td align="left" colspan="1" rowspan="1">0.215–1.060</td>
<td align="left" colspan="1" rowspan="1">0.069</td>
<td align="left" colspan="1" rowspan="1">3.300</td>
<td align="left" colspan="1" rowspan="1">−0.740</td>
<td align="left" colspan="1" rowspan="1">0.407</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Lines</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 2</td>
<td align="left" colspan="1" rowspan="1">1.234</td>
<td align="left" colspan="1" rowspan="1">0.751–2.028</td>
<td align="left" colspan="1" rowspan="1">0.407</td>
<td align="left" colspan="1" rowspan="1">0.687</td>
<td align="left" colspan="1" rowspan="1">0.210</td>
<td align="left" colspan="1" rowspan="1">0.254</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 2</td>
<td align="left" colspan="1" rowspan="1">2.634</td>
<td align="left" colspan="1" rowspan="1">1.531–4.533</td>
<td align="left" colspan="1" rowspan="1"> &lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">12.229</td>
<td align="left" colspan="1" rowspan="1">0.968</td>
<td align="left" colspan="1" rowspan="1">0.277</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">ECOG PS</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0 ~ 1</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> &gt; 2</td>
<td align="left" colspan="1" rowspan="1">1.404</td>
<td align="left" colspan="1" rowspan="1">0.869–2.271</td>
<td align="left" colspan="1" rowspan="1">0.166</td>
<td align="left" colspan="1" rowspan="1">1.920</td>
<td align="left" colspan="1" rowspan="1">0.340</td>
<td align="left" colspan="1" rowspan="1">0.245</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Efficacy assessment</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PD</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> SD</td>
<td align="left" colspan="1" rowspan="1">0.568</td>
<td align="left" colspan="1" rowspan="1">0.387–0.833</td>
<td align="left" colspan="1" rowspan="1">0.004</td>
<td align="left" colspan="1" rowspan="1">8.381</td>
<td align="left" colspan="1" rowspan="1">−0.566</td>
<td align="left" colspan="1" rowspan="1">0.195</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> PR</td>
<td align="left" colspan="1" rowspan="1">0.213</td>
<td align="left" colspan="1" rowspan="1">0.104–0.435</td>
<td align="left" colspan="1" rowspan="1"> &lt; 0.001</td>
<td align="left" colspan="1" rowspan="1">18.008</td>
<td align="left" colspan="1" rowspan="1">−1.547</td>
<td align="left" colspan="1" rowspan="1">0.365</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">AE grade</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 0</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 1 ~ 2</td>
<td align="left" colspan="1" rowspan="1">0.681</td>
<td align="left" colspan="1" rowspan="1">0.468–0.990</td>
<td align="left" colspan="1" rowspan="1">0.044</td>
<td align="left" colspan="1" rowspan="1">4.042</td>
<td align="left" colspan="1" rowspan="1">−0.384</td>
<td align="left" colspan="1" rowspan="1">0.191</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> 3 + </td>
<td align="left" colspan="1" rowspan="1">1.204</td>
<td align="left" colspan="1" rowspan="1">0.673–2.153</td>
<td align="left" colspan="1" rowspan="1">0.532</td>
<td align="left" colspan="1" rowspan="1">0.391</td>
<td align="left" colspan="1" rowspan="1">0.186</td>
<td align="left" colspan="1" rowspan="1">0.297</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Liver metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">2.514</td>
<td align="left" colspan="1" rowspan="1">1.217–5.195</td>
<td align="left" colspan="1" rowspan="1">0.013</td>
<td align="left" colspan="1" rowspan="1">6.199</td>
<td align="left" colspan="1" rowspan="1">0.922</td>
<td align="left" colspan="1" rowspan="1">0.370</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Bone metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">1.509</td>
<td align="left" colspan="1" rowspan="1">0.913–2.495</td>
<td align="left" colspan="1" rowspan="1">0.109</td>
<td align="left" colspan="1" rowspan="1">2.573</td>
<td align="left" colspan="1" rowspan="1">0.411</td>
<td align="left" colspan="1" rowspan="1">0.257</td>
</tr>
<tr><td align="left" colspan="7" rowspan="1">Other metastases</td></tr>
<tr>
<td align="left" colspan="1" rowspan="1"> No</td>
<td align="left" colspan="1" rowspan="1">Ref</td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
<td align="left" colspan="1" rowspan="1"></td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1"> Yes</td>
<td align="left" colspan="1" rowspan="1">0.673</td>
<td align="left" colspan="1" rowspan="1">0.403–1.122</td>
<td align="left" colspan="1" rowspan="1">0.129</td>
<td align="left" colspan="1" rowspan="1">2.309</td>
<td align="left" colspan="1" rowspan="1">−0.396</td>
<td align="left" colspan="1" rowspan="1">0.261</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/Tab2/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p26"><p><em>WBC</em> White blood cell count, <em>CEA</em> Carcinoembryonic antigen, <em>NEU_LYM</em> Neutrophil/lymphocyte ratio, <em>AATs</em> Anti-angiogenesis therapies, <em>ECOG PS</em> Eastern Cooperative Oncology Group Performance Status, <em>AE</em> Adverse event, <em>PD</em> Progressive disease, <em>PR</em> Partial response, <em>SD</em> Stable disease</p></div></div></section><figure class="fig xbox font-sm" id="Fig3"><h4 class="obj_head">Fig. 3.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig3_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/5bd493b84059/12885_2025_14559_Fig3_HTML.jpg" loading="lazy" id="d33e2618" height="276" width="669" alt="Fig. 3"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig3/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Nomograms for predicting 12-, 24-, and 36-month OS (<strong>a</strong>) and PFS (<strong>b</strong>) in lung cancer patients. NLR: Neutrophil to lymphocyte count ratio</p></figcaption></figure></section><section id="Sec15"><h3 class="pmc_sec_title">Validation of predictive models</h3>
<p id="Par42">In the training set, the C-index values were 0.709 (95% CI: 0.666–0.752) for OS and 0.730 (95% CI: 0.698–0.763) for PFS. In the validation set, the C-index values were 0.655 (95% CI: 0.588–0.722) for OS and 0.694 (95% CI: 0.637–0.751) for PFS. The effectiveness of the risk prediction models for OS and PFS was assessed using the area under the receiver operating characteristic (ROC) curve (AUC). The ROC curves from the training set show AUC values for OS and PFS at 12, 24, and 36 months as follows: for OS, 0.745 (95% CI: 0.680–0.809), 0.733 (95% CI: 0.664–0.801), 0.731 (95% CI: 0.641–0.821); for PFS, 0.801 (95% CI: 0.748–0.853), 0.815 (95% CI: 0.749–0.880), 0.848 (95% CI: 0.781–0.915). In the validation set, AUC values for OS at 12, 24, and 36 months were 0.676 (95% CI: 0.564–0.787), 0.720 (95% CI: 0.613–0.827), 0.707 (95% CI: 0.569–0.845); for PFS, they were 0.789 (95% CI: 0.704–0.873), 0.882 (95% CI: 0.824–0.941), 0.837 (95% CI: 0.752–0.992), as shown in Fig. <a href="#Fig4" class="usa-link">4</a>. Calibration curves from both the training and validation sets show a high level of concordance between the predicted and actual OS values, as demonstrated by nomogram 1. Similarly, Nomogram 2's predicted PFS values closely align with the observed values, as shown in Fig. <a href="#Fig5" class="usa-link">5</a>. These results confirm the robust performance of our prediction models.</p>
<figure class="fig xbox font-sm" id="Fig4"><h4 class="obj_head">Fig. 4.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig4_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/c6b591e4e78f/12885_2025_14559_Fig4_HTML.jpg" loading="lazy" id="MO4" height="750" width="778" alt="Fig. 4"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig4/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>The time-dependent ROC curves of nomogram predicting OS and PFS. <strong>a</strong> and <strong>b</strong>, 12-month, 24-month, and 36-month OS and PFS in the validation set; <strong>c</strong> and <strong>d</strong>, 12-month, 24-month, and 36-month OS and PFS in the training set. ROC, receiver operating characteristic; OS, Overall Survival; PFS, Progress Free Survival</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig5"><h4 class="obj_head">Fig. 5.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig5_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/3900f0a8bfe5/12885_2025_14559_Fig5_HTML.jpg" loading="lazy" id="MO5" height="737" width="778" alt="Fig. 5"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig5/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Calibration curves used to predict OS and PFS. <strong>a</strong> and <strong>b</strong>, 12-month, 24-month, and 36-month OS and PFS in the validation set; <strong>c</strong> and (<strong>d</strong>), 12-month, 24-month, and 36-month OS and PFS in the training set. OS, Overall Survival; PFS, Progress Free Survival</p></figcaption></figure></section><section id="Sec16"><h3 class="pmc_sec_title">Clinical application of nomogram</h3>
<p id="Par43">Decision Curve Analysis (DCA) was used to evaluate the clinical utility of the nomograms for OS and PFS, showing favorable outcomes in both the training and validation sets (Figs. <a href="#Fig6" class="usa-link">6</a> and <a href="#Fig7" class="usa-link">7</a>). Using risk scores and cutoff values from the nomograms, patients were categorized into high-risk (OS ≥ 161.580, PFS ≥ 9.780) and low-risk (OS &lt; 161.580, PFS &lt; 9.780) groups. In the high-risk group, median overall survival (mOS) was 16.3 months and median progression-free survival (mPFS) was 5.5 months, with 95% confidence intervals of 0.428–0.579 and 0.438–0.560, respectively. For the low-risk group, the mOS was 45.9 months and mPFS was 35.1 months, with 95% confidence intervals of 0.400–0.611 and 0.427–0.624, respectively. The Kaplan–Meier curves validate that the risk prediction model effectively forecasts both OS and PFS (Fig. <a href="#Fig8" class="usa-link">8</a>a and b). There was a significant correlation between the model's low-risk prediction and extended OS, as well as prolonged PFS, both with <em>P</em>-values &lt; 0.001.</p>
<figure class="fig xbox font-sm" id="Fig6"><h4 class="obj_head">Fig. 6.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig6_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/1b7844b66d07/12885_2025_14559_Fig6_HTML.jpg" loading="lazy" id="d33e2691" height="1016" width="670" alt="Fig. 6"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig6/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>DCA of nomogram. Analysis of decision curves for 12-, 24-, and 36-month OS and PFS in the validation set. Blue line: All patients died. Green line: No patient died. Red line: nomogram model. DCA: Decision curve analysis</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig7"><h4 class="obj_head">Fig. 7.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig7_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/006575c5c539/12885_2025_14559_Fig7_HTML.jpg" loading="lazy" id="d33e2698" height="1016" width="670" alt="Fig. 7"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig7/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>DCA of nomogram. Analysis of decision curves for 12-, 24-, and 36-month OS and PFS in the training set. Blue line: All patients died. Green line: No patient died. Red line: nomogram model. DCA: Decision curve analysis</p></figcaption></figure><figure class="fig xbox font-sm" id="Fig8"><h4 class="obj_head">Fig. 8.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12372320_12885_2025_14559_Fig8_HTML.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2106/12372320/857de3116071/12885_2025_14559_Fig8_HTML.jpg" loading="lazy" id="MO8" height="354" width="778" alt="Fig. 8"></a></p>
<div class="p text-right font-secondary"><a href="figure/Fig8/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Kaplan–Meier survival analysis. Patients were divided into high and low risk groups based on risk scores and optimal cutoff values derived from nomograms for OS and PFS. <strong>a</strong> Kaplan–Meier curve of OS. <strong>b</strong> Kaplan–Meier curve of PFS</p></figcaption></figure></section></section><section id="Sec17"><h2 class="pmc_sec_title">Discuss</h2>
<p id="Par44">Accurately predicting tumor prognosis following treatment is essential for optimizing patient management and individualizing therapy. This study identified independent risk factors for OS and PFS at 12, 24, and 36 months in lung cancer patients using our training set. We developed and validated two novel nomograms to predict these outcomes at the corresponding time points. Nomogram 1 incorporates several factors, including the NLR, surgical history, clinical staging, treatment lines, efficacy assessments, immune-related adverse events (irAEs), and the presence of liver metastases. Nomogram 2 includes treatment lines, efficacy assessments, ascites, and the presence of lung, bone, lymph node, and other metastatic sites. Both nomograms demonstrated superior differentiability, achieving C-index values for OS and PFS of 0.709 and 0.730 in the training cohort, and 0.655 and 0.694 in the validation cohort. Subsequent calibration curves and decision curve analyses confirmed the predictive accuracy and clinical utility of both nomograms, with predictions closely aligning with observed outcomes.</p>
<p id="Par45">We identified eight key predictors for lung cancer prognosis: NLR, surgical history, cancer stage, ascites, baseline metastatic sites, treatment lines, efficacy assessments, and immune-associated adverse events. The relationship between inflammation and cancer is multifaceted; NLR, as a blood-based inflammation marker, has shown effectiveness in prognostic evaluation across various cancer types [<a href="#CR25" class="usa-link" aria-describedby="CR25">25</a>]. Specifically, studies indicate that NLR serves as a reliable prognostic biomarker for lung cancer patients undergoing immunotherapy [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>]. Our findings are consistent with a large review by Chen et al. [<a href="#CR27" class="usa-link" aria-describedby="CR27">27</a>], which revealed that patients with non-small cell lung cancer (NSCLC) exhibiting reduced NLR levels at weeks 6 and 12 following immunotherapy had longer PFS and OS compared to those with elevated NLR (<em>P</em> &lt; 0.001). This emphasizes the viability of using baseline NLR as a biomarker for lung cancer prognosis, reinforcing the effectiveness of our risk prediction model. Importantly, NLR data can be readily obtained from routine blood tests, offering a cost-effective and convenient prognostic tool, although it is essential to account for potential confounding factors related to comorbidities and treatments [<a href="#CR26" class="usa-link" aria-describedby="CR26">26</a>, <a href="#CR28" class="usa-link" aria-describedby="CR28">28</a>, <a href="#CR29" class="usa-link" aria-describedby="CR29">29</a>].</p>
<p id="Par46">Common metastatic sites for lung cancer, including bones, brain, lungs, and liver, significantly influence patient prognosis [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR31" class="usa-link" aria-describedby="CR31">31</a>]. Patients presenting with metastases at baseline experienced poorer outcomes. A systematic meta-analysis revealed that patients with brain, liver, or bone metastases exhibited reduced OS when treated with PD-1 inhibitors. Similarly, brain and liver metastases were associated with higher progression rates under PD-1 inhibitor treatment. Patients with multiple metastatic sites showed worse PFS than those with a single site, with no significant difference in OS observed. Multiple organ metastases are frequently correlated with poor physical condition and cancer-related cachexia. The metastatic site independently predicts survival outcomes in advanced NSCLC patients treated with PD-1 inhibitors [<a href="#CR32" class="usa-link" aria-describedby="CR32">32</a>]. Research consistently shows that patients with metastases at baseline experience poorer outcomes. A systematic meta-analysis corroborated that patients with brain, liver, or bone metastases exhibit reduced overall survival when treated with PD-1 inhibitors. Furthermore, multiple metastatic sites correlate with worse progression-free survival compared to a single site, though no significant differences in OS have been observed. Malignant pleural effusion was found to be an independent prognostic risk factor for PFS in our study; patients without pre-existing fluid accumulation fared better than those with it. Previous studies have identified malignant pleural effusion as a negative predictor of PFS due in part to its association with tumor-induced immunosuppression [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR33" class="usa-link" aria-describedby="CR33">33</a>]. Kawachi et al. proposed that vascular endothelial growth factor (VEGF) mediates pleural effusion's adverse effects by increasing vascular permeability, which can impair response to treatment. Elevated VEGF levels in patients with malignant pleural effusion have been associated with poor responses to pembrolizumab monotherapy, indicating a critical area for further investigation [<a href="#CR30" class="usa-link" aria-describedby="CR30">30</a>, <a href="#CR34" class="usa-link" aria-describedby="CR34">34</a>, <a href="#CR35" class="usa-link" aria-describedby="CR35">35</a>].</p>
<p id="Par47">We observed that treatment lines and clinical stage were independent predictors for both PFS and OS. Notably, patients receiving immune checkpoint inhibitors (ICIs) as first-line therapy showed significant benefits. Comparative analyses revealed that pembrolizumab demonstrated a 5-year survival rate of 32% as a first-line treatment in advanced NSCLC patients with a PD-L1 expression of ≥ 50% [<a href="#CR36" class="usa-link" aria-describedby="CR36">36</a>]. Randomized trials have also indicated the advantage of ICIs over standard chemotherapy in second-line settings [<a href="#CR37" class="usa-link" aria-describedby="CR37">37</a>]. Interestingly, our findings indicated that patients treated with ICIs in the second-line setting experienced improved PFS compared to those receiving first-line treatment. This phenomenon may be attributed to the initial use of chemotherapy, which can modify the tumor microenvironment favorably, enhancing subsequent immunotherapy responses. Prior studies have shown that preconditioning with chemotherapy alters the cellular composition of the tumor microenvironment, enhancing the efficacy of immune checkpoint inhibitors [<a href="#CR38" class="usa-link" aria-describedby="CR38">38</a>]. Analyzing drug resistance mechanisms and optimizing immunotherapy [<a href="#CR39" class="usa-link" aria-describedby="CR39">39</a>] could improve outcomes in second-line treatments. Clinicians may choose a more appropriate immunotherapy or combination regimen for second-line treatment, based on patient response to first-line therapy and resistance mechanisms. Individualized therapeutic optimization can enhance the efficacy and PFS of second-line immunotherapies.</p>
<p id="Par48">With the increasing availability and efficacy of ICI therapies, concerns regarding treatment-specific toxicities, particularly immune-related adverse events, are growing [<a href="#CR40" class="usa-link" aria-describedby="CR40">40</a>]. These events are often interpreted as indicators of enhanced immune responses and improved anti-tumor efficacy [<a href="#CR41" class="usa-link" aria-describedby="CR41">41</a>]. Consequently, numerous studies have explored whether these events could serve as indicators of ICI efficacy in cancer treatment. Emerging data suggest that irAEs may correlate with increased efficacy of ICIs in advanced malignancies such as NSCLC, indicating that patients who discontinue therapy due to irAEs might still experience therapeutic benefits [<a href="#CR42" class="usa-link" aria-describedby="CR42">42</a>–<a href="#CR44" class="usa-link" aria-describedby="CR44">44</a>]. Interestingly, our study found that patients experiencing grade 1–2 irAEs had longer OS compared to those without such events or those with severe irAEs. This observation aligns with findings from large clinical trials indicating that lower-grade irAEs are associated with better treatment outcomes, suggesting that irAEs may reflect effective immune activation and significant treatment responses [<a href="#CR45" class="usa-link" aria-describedby="CR45">45</a>–<a href="#CR48" class="usa-link" aria-describedby="CR48">48</a>].</p>
<p id="Par49">The nomograms provide a practical tool for stratifying ICI-treated patients into low- and high-risk groups, guiding decisions on therapy escalation (e.g., combination regimens) or palliative care. For example, high-risk patients (OS &lt; 16 months) may benefit from early integration of anti-angiogenic agents or clinical trials targeting TME immunosuppression. However, challenges include biomarker accessibility in resource-limited settings and the need for real-time NLR/CEA monitoring. While the nomogram's calculations are straightforward (summing weighted scores), integration into electronic health records requires user-friendly interfaces to minimize computational burden.</p>
<p id="Par50">As a real-world study, our findings are subject to inherent limitations. Conducted retrospectively at a single institution, the results may have limited generalizability. The small sample size and the non-randomized nature of participant selection may introduce biases. To validate these findings, large-scale, multicenter clinical trials involving diverse patient populations are warranted. Additionally, the relatively short follow-up period necessitates ongoing monitoring and extended evaluations. Our study's approach, which assessed lung cancer patients prior to ICI treatment while considering clinical, pathological, and laboratory characteristics, generates valuable data that could assist in predicting lung cancer prognosis after immunotherapy.</p></section><section id="Sec18"><h2 class="pmc_sec_title">Conclusion</h2>
<p id="Par51">In conclusion, this study successfully identifies and validates critical prognostic factors for lung cancer treatment outcomes, culminating in the development of two effective nomograms. These tools hold significant promise for enhancing individualized treatment strategies and improving patient prognostication in clinical settings. Further research and validation in larger cohorts are required to ensure their broader applicability and optimization in the management of lung cancer.</p></section><section id="ack1" class="ack"><h2 class="pmc_sec_title">Acknowledgements</h2>
<p>We would like to express our sincere gratitude to all individuals and organizations that contributed to this research. We also acknowledge the financial support provided by Jiangsu Provincial Medical Key Discipline(Laboratory) (N0. ZDXYS202208); Postdoctoral Fellowship Fund of Jinling Hospital Affiliated to Nanjing University Medical School (No.96727); Project supported by Nanjing Medical Science and technology development (No. ZKX22026). These funding made it possible for us to conduct this research and complete this manuscript.</p></section><section id="glossary1" class="glossary"><h2 class="pmc_sec_title">Abbreviations</h2>
<dl class="def-list">
<dt>PFS</dt>
<dd><p id="Par5">Progression-free survival</p></dd>
<dt>OS</dt>
<dd><p id="Par6">Overall survival</p></dd>
<dt>C-index</dt>
<dd><p id="Par7">Concordance index</p></dd>
<dt>ROC</dt>
<dd><p id="Par8">Receiver operating characteristic</p></dd>
<dt>DCA</dt>
<dd><p id="Par9">Decision curve analyses</p></dd>
<dt>ECOG PS</dt>
<dd><p id="Par10">Eastern Cooperative Oncology Group Performance Status</p></dd>
<dt>WBC</dt>
<dd><p id="Par11">White blood cell count</p></dd>
<dt>CEA</dt>
<dd><p id="Par12">Carcinoembryonic antigen</p></dd>
<dt>NLR</dt>
<dd><p id="Par13">Neutrophil-to-lymphocyte ratio</p></dd>
<dt>PLR</dt>
<dd><p id="Par14"> Platelet-to-lymphocyte ratio</p></dd>
<dt>HGB</dt>
<dd><p id="Par15">Hemoglobin</p></dd>
<dt>CA125</dt>
<dd><p id="Par16">Carbohydrate antigen 125</p></dd>
<dt>CA199</dt>
<dd><p id="Par17"> Carbohydrate antigen 199</p></dd>
<dt>AATs</dt>
<dd><p id="Par18">Anti-angiogenesis therapies</p></dd>
<dt>ICIs</dt>
<dd><p id="Par19">Immune checkpoint inhibitors</p></dd>
<dt>PD-1</dt>
<dd><p id="Par20">Anti-programmed death-1</p></dd>
<dt>PD-L1</dt>
<dd><p id="Par21">Anti-programmed death ligand-1</p></dd>
<dt>CTLA4</dt>
<dd><p id="Par22">Anti-cytotoxic T lymphocyte antigen 4</p></dd>
<dt>PD</dt>
<dd><p id="Par23">Progressive disease</p></dd>
<dt>PR</dt>
<dd><p id="Par24">Partial response</p></dd>
<dt>SD</dt>
<dd><p id="Par25">Stable disease</p></dd>
</dl></section><section id="notes1"><h2 class="pmc_sec_title">Authors’ contributions</h2>
<p>Conceptualization: CXY, CC and YM. Data curation: CC. Formal analysis: QJ. Funding acquisition: CC, QJ and YM. Investigation: LTW, CA and HN. Methodology: OYT, ZF and YY. Software: OYT. Validation: CC. Visualization: ZF. Writing - original draft: OYT. Writing - review &amp; editing: CXY, CC and YM. All authors reviewed the manuscript.</p></section><section id="notes2"><h2 class="pmc_sec_title">Funding</h2>
<p>The study was supported by Jiangsu Provincial Medical Key Discipline(Laboratory) (N0. ZDXYS202208); Postdoctoral Fellowship Fund of Jinling Hospital Affiliated to Nanjing University Medical School (No.96727); Project supported by Nanjing Medical Science and technology development (No. ZKX22026).</p></section><section id="notes3"><h2 class="pmc_sec_title">Data availability</h2>
<p>The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.</p></section><section id="notes4"><h2 class="pmc_sec_title">Declarations</h2>
<section id="FPar1"><h3 class="pmc_sec_title">Ethics approval and consent to participate</h3>
<p id="Par52">All procedures performed in this study involving human participants were in accordance with the guidelines of the Ethics Committee of Nanjing University School of Medicine affiliated Jinling Hospital (No. DZQH-KYLL-23-06) and with the 1964 Helsinki Declaration. Patients treated in our hospital will be informed of the potential research use of personal information. Only patients who agreed with and signed the consent were included in our study.</p></section><section id="FPar2"><h3 class="pmc_sec_title">Consent for publication</h3>
<p id="Par53">Not applicable.</p></section><section id="FPar3"><h3 class="pmc_sec_title">Competing interests</h3>
<p id="Par54">The authors declare no competing interests.</p></section></section><section id="fn-group1" class="fn-group"><h2 class="pmc_sec_title">Footnotes</h2>
<div class="fn-group p font-secondary-light font-sm">
<div class="fn p" id="fn1">
<p><strong>Publisher’s Note</strong></p>
<p>Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.</p>
</div>
<div class="fn p" id="fn2"><p>Ting Ouyang, Fei Zhang and Yan Yang contributed equally to this work.</p></div>
</div></section><section id="_ci93_" lang="en" class="contrib-info"><h2 class="pmc_sec_title">Contributor Information</h2>
<p>Xiaoyuan Chu, Email: chuxiaoyuan000@163.com.</p>
<p>Chao Chen, Email: njjloncologycc@163.com.</p>
<p>Mi Yang, Email: yangmi@nju.edu.cn.</p></section><section id="Bib1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="Bib1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="CR1">
<span class="label">1.</span><cite>Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Glo bal cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229–63.
</cite> [<a href="https://doi.org/10.3322/caac.21834" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38572751/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Bray%20F,%20Laversanne%20M,%20Sung%20H,%20Ferlay%20J,%20Siegel%20RL,%20Soerjomataram%20I,%20et%20al.%20Glo%20bal%20cancer%20statistics%202022:%20GLOBOCAN%20estimates%20of%20incidence%20and%20mortality%20worldwide%20for%2036%20cancers%20in%20185%20countries.%20CA%20Cancer%20J%20Clin.%202024;74(3):229%E2%80%9363." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR2">
<span class="label">2.</span><cite>Zheng RS, Chen R, Han BF, Wang SM, Li L, Sun KX, et al. Cancer incidence and mortality in China, 2022. Zhonghua Zhong Liu Za Zhi. 2024;46(3):221–31.
</cite> [<a href="https://doi.org/10.3760/cma.j.cn112152-20240119-00035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38468501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zheng%20RS,%20Chen%20R,%20Han%20BF,%20Wang%20SM,%20Li%20L,%20Sun%20KX,%20et%20al.%20Cancer%20incidence%20and%20mortality%20in%20China,%202022.%20Zhonghua%20Zhong%20Liu%20Za%20Zhi.%202024;46(3):221%E2%80%9331." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR3">
<span class="label">3.</span><cite>de Castro G Jr, Kudaba I, Wu YL, Lopes G, Kowalski DM, Turna HZ, et al. Five-year outcomes with pembrolizumab versus chemotherapy as first-line therapy in patients with non-small-cell lung cancer and programmed death ligand-1 tumor proportion score ≥ 1% in the KEYNOTE-042 study. J Clin Oncol. 2023;41(11):1986–91.
</cite> [<a href="https://doi.org/10.1200/JCO.21.02885" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10082298/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36306479/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?de%20Castro%20G%20Jr,%20Kudaba%20I,%20Wu%20YL,%20Lopes%20G,%20Kowalski%20DM,%20Turna%20HZ,%20et%20al.%20Five-year%20outcomes%20with%20pembrolizumab%20versus%20chemotherapy%20as%20first-line%20therapy%20in%20patients%20with%20non-small-cell%20lung%20cancer%20and%20programmed%20death%20ligand-1%20tumor%20proportion%20score%20%E2%89%A5%201%%20in%20the%20KEYNOTE-042%20study.%20J%20Clin%20Oncol.%202023;41(11):1986%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR4">
<span class="label">4.</span><cite>Rudin CM, Awad MM, Navarro A, Gottfried M, Peters S, Csőszi T, et al. Pembrolizumab or placebo plus etoposide and platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study. J Clin Oncol. 2020;38(21):2369–79.
</cite> [<a href="https://doi.org/10.1200/JCO.20.00793" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7474472/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32468956/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Rudin%20CM,%20Awad%20MM,%20Navarro%20A,%20Gottfried%20M,%20Peters%20S,%20Cs%C5%91szi%20T,%20et%20al.%20Pembrolizumab%20or%20placebo%20plus%20etoposide%20and%20platinum%20as%20first-line%20therapy%20for%20extensive-stage%20small-cell%20lung%20cancer:%20randomized,%20double-blind,%20phase%20III%20KEYNOTE-604%20study.%20J%20Clin%20Oncol.%202020;38(21):2369%E2%80%9379." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR5">
<span class="label">5.</span><cite>Salas-Benito D, Pérez-Gracia JL, Ponz-Sarvisé M, Rodriguez-Ruiz ME, Martínez-Forero I, Castañón E, et al. Paradigms on immunotherapy combinations with chemotherapy. Cancer Discov. 2021;11(6):1353–67.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-20-1312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33712487/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Salas-Benito%20D,%20P%C3%A9rez-Gracia%20JL,%20Ponz-Sarvis%C3%A9%20M,%20Rodriguez-Ruiz%20ME,%20Mart%C3%ADnez-Forero%20I,%20Casta%C3%B1%C3%B3n%20E,%20et%20al.%20Paradigms%20on%20immunotherapy%20combinations%20with%20chemotherapy.%20Cancer%20Discov.%202021;11(6):1353%E2%80%9367." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR6">
<span class="label">6.</span><cite>Jin R, Liu C, Zheng S, Wang X, Feng X, Li H, et al. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer. Cancer Biol Med. 2020;17(3):768–81.
</cite> [<a href="https://doi.org/10.20892/j.issn.2095-3941.2020.0121" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7476088/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32944405/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20R,%20Liu%20C,%20Zheng%20S,%20Wang%20X,%20Feng%20X,%20Li%20H,%20et%20al.%20Molecular%20heterogeneity%20of%20anti-PD-1/PD-L1%20immunotherapy%20efficacy%20is%20correlated%20with%20tumor%20immune%20microenvironment%20in%20East%20Asian%20patients%20with%20non-small%20cell%20lung%20cancer.%20Cancer%20Biol%20Med.%202020;17(3):768%E2%80%9381." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR7">
<span class="label">7.</span><cite>Sun L, Bleiberg B, Hwang WT, Marmarelis ME, Langer CJ, Singh A, et al. Association between duration of immunotherapy and overall survival in advanced non-small cell lung cancer. JAMA Oncol. 2023;9(8):1075–82.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2023.1891" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10240399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37270700/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Sun%20L,%20Bleiberg%20B,%20Hwang%20WT,%20Marmarelis%20ME,%20Langer%20CJ,%20Singh%20A,%20et%20al.%20Association%20between%20duration%20of%20immunotherapy%20and%20overall%20survival%20in%20advanced%20non-small%20cell%20lung%20cancer.%20JAMA%20Oncol.%202023;9(8):1075%E2%80%9382." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR8">
<span class="label">8.</span><cite>Gainor JF, Rizvi H, Jimenez Aguilar E, Skoulidis F, Yeap BY, Naidoo J, et al. Clinical activity of programmed cell death 1 (PD-1) blockade in never, light, and heavy smokers with non-small-cell lung cancer and PD-L1 expression ≥50. Ann Oncol. 2020;31(3):404–11.
</cite> [<a href="https://doi.org/10.1016/j.annonc.2019.11.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7545963/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32067682/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Gainor%20JF,%20Rizvi%20H,%20Jimenez%20Aguilar%20E,%20Skoulidis%20F,%20Yeap%20BY,%20Naidoo%20J,%20et%20al.%20Clinical%20activity%20of%20programmed%20cell%20death%201%20(PD-1)%20blockade%20in%20never,%20light,%20and%20heavy%20smokers%20with%20non-small-cell%20lung%20cancer%20and%20PD-L1%20expression%20%E2%89%A550.%20Ann%20Oncol.%202020;31(3):404%E2%80%9311." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR9">
<span class="label">9.</span><cite>Kim ES, Velcheti V, Mekhail T, Yun C, Shagan SM, Hu S, et al. Blood-based tumor mutational burden as a biomarker for atezolizumab in non-small cell lung cancer: the phase 2 B-F1RST trial. Nat Med. 2022;28(5):939–45.
</cite> [<a href="https://doi.org/10.1038/s41591-022-01754-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9117143/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35422531/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kim%20ES,%20Velcheti%20V,%20Mekhail%20T,%20Yun%20C,%20Shagan%20SM,%20Hu%20S,%20et%20al.%20Blood-based%20tumor%20mutational%20burden%20as%20a%20biomarker%20for%20atezolizumab%20in%20non-small%20cell%20lung%20cancer:%20the%20phase%202%20B-F1RST%20trial.%20Nat%20Med.%202022;28(5):939%E2%80%9345." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR10">
<span class="label">10.</span><cite>Tostes K, Siqueira AP, Reis RM, Leal LF, Arantes L. Biomarkers for immune checkpoint inhibitor response in NSCLC: current developments and applicability. Int J Mol Sci. 2023. 10.3390/ijms241511887.
</cite> [<a href="https://doi.org/10.3390/ijms241511887" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10418476/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37569262/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Tostes%20K,%20Siqueira%20AP,%20Reis%20RM,%20Leal%20LF,%20Arantes%20L.%20Biomarkers%20for%20immune%20checkpoint%20inhibitor%20response%20in%20NSCLC:%20current%20developments%20and%20applicability.%20Int%20J%20Mol%20Sci.%202023.%2010.3390/ijms241511887." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR11">
<span class="label">11.</span><cite>Negrao MV, Skoulidis F, Montesion M, Schulze K, Bara I, Shen V, et al. Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer. J Immunother Cancer. 2021. 10.1136/jitc-2021-002891.
</cite> [<a href="https://doi.org/10.1136/jitc-2021-002891" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8356172/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34376553/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Negrao%20MV,%20Skoulidis%20F,%20Montesion%20M,%20Schulze%20K,%20Bara%20I,%20Shen%20V,%20et%20al.%20Oncogene-specific%20differences%20in%20tumor%20mutational%20burden,%20PD-L1%20expression,%20and%20outcomes%20from%20immunotherapy%20in%20non-small%20cell%20lung%20cancer.%20J%20Immunother%20Cancer.%202021.%2010.1136/jitc-2021-002891." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR12">
<span class="label">12.</span><cite>Johnson ML, Cho BC, Luft A, Alatorre-Alexander J, Geater SL, Laktionov K, et al. Durvalumab with or without tremelimumab in combination with chemotherapy as first-line therapy for metastatic non-small-cell lung cancer: the phase III POSEIDON study. J Clin Oncol. 2023;41(6):1213–27.
</cite> [<a href="https://doi.org/10.1200/JCO.22.00975" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9937097/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36327426/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Johnson%20ML,%20Cho%20BC,%20Luft%20A,%20Alatorre-Alexander%20J,%20Geater%20SL,%20Laktionov%20K,%20et%20al.%20Durvalumab%20with%20or%20without%20tremelimumab%20in%20combination%20with%20chemotherapy%20as%20first-line%20therapy%20for%20metastatic%20non-small-cell%20lung%20cancer:%20the%20phase%20III%20POSEIDON%20study.%20J%20Clin%20Oncol.%202023;41(6):1213%E2%80%9327." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR13">
<span class="label">13.</span><cite>Liu M, Wei F, Wang J, Yu W, Shen M, Liu T, et al. Myeloid-derived suppressor cells regulate the immunosuppressive functions of PD-1(-)PD-L1(+) Bregs through PD-L1/PI3K/AKT/NF-κB axis in breast cancer. Cell Death Dis. 2021;12(5):465.
</cite> [<a href="https://doi.org/10.1038/s41419-021-03745-1" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8107179/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33967272/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20M,%20Wei%20F,%20Wang%20J,%20Yu%20W,%20Shen%20M,%20Liu%20T,%20et%20al.%20Myeloid-derived%20suppressor%20cells%20regulate%20the%20immunosuppressive%20functions%20of%20PD-1(-)PD-L1(+)%20Bregs%20through%20PD-L1/PI3K/AKT/NF-%CE%BAB%20axis%20in%20breast%20cancer.%20Cell%20Death%20Dis.%202021;12(5):465." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR14">
<span class="label">14.</span><cite>Huang J, Cai X, Ng C, Luo Y, Chen Q, Wang Z, et al. A phase 2 study of tislelizumab as neoadjuvant treatment of cisplatin-ineligible high-risk upper tract urothelial carcinoma. J Urol. 2025;213(6):739–52.
</cite> [<a href="https://doi.org/10.1097/JU.0000000000004475" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39999445/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Huang%20J,%20Cai%20X,%20Ng%20C,%20Luo%20Y,%20Chen%20Q,%20Wang%20Z,%20et%20al.%20A%20phase%202%20study%20of%20tislelizumab%20as%20neoadjuvant%20treatment%20of%20cisplatin-ineligible%20high-risk%20upper%20tract%20urothelial%20carcinoma.%20J%20Urol.%202025;213(6):739%E2%80%9352." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR15">
<span class="label">15.</span><cite>Zhang M, Cui J, Chen H, Cheng Y, Chen Q, Zong F, et al. Increased SOAT2 expression in aged regulatory T cells is associated with altered cholesterol metabolism and reduced anti-tumor immunity. Nat Commun. 2025;16(1):630.
</cite> [<a href="https://doi.org/10.1038/s41467-025-56002-w" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11729894/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39805872/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20M,%20Cui%20J,%20Chen%20H,%20Cheng%20Y,%20Chen%20Q,%20Zong%20F,%20et%20al.%20Increased%20SOAT2%20expression%20in%20aged%20regulatory%20T%20cells%20is%20associated%20with%20altered%20cholesterol%20metabolism%20and%20reduced%20anti-tumor%20immunity.%20Nat%20Commun.%202025;16(1):630." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR16">
<span class="label">16.</span><cite>Liu X, Xi X, Xu S, Chu H, Hu P, Li D, et al. Targeting T cell exhaustion: emerging strategies in non-small cell lung cancer. Front Immunol. 2024;15:1507501.
</cite> [<a href="https://doi.org/10.3389/fimmu.2024.1507501" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11669709/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39726592/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Liu%20X,%20Xi%20X,%20Xu%20S,%20Chu%20H,%20Hu%20P,%20Li%20D,%20et%20al.%20Targeting%20T%20cell%20exhaustion:%20emerging%20strategies%20in%20non-small%20cell%20lung%20cancer.%20Front%20Immunol.%202024;15:1507501." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR17">
<span class="label">17.</span><cite>Xu S, Lu Z. Exploring FNDC4 as a biomarker for prognosis and immunotherapy response in lung adenocarcinoma. Asian journal of surgery 2024.</cite> [<a href="https://doi.org/10.1016/j.asjsur.2024.09.054" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39277471/" class="usa-link">PubMed</a>]</li>
<li id="CR18">
<span class="label">18.</span><cite>Teng F, Meng X, Kong L, Yu J. Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: a systematic review. Cancer Lett. 2018;414:166–73.
</cite> [<a href="https://doi.org/10.1016/j.canlet.2017.11.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29155348/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teng%20F,%20Meng%20X,%20Kong%20L,%20Yu%20J.%20Progress%20and%20challenges%20of%20predictive%20biomarkers%20of%20anti%20PD-1/PD-L1%20immunotherapy:%20a%20systematic%20review.%20Cancer%20Lett.%202018;414:166%E2%80%9373." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR19">
<span class="label">19.</span><cite>Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.
</cite> [<a href="https://doi.org/10.1038/nature14011" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4836193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25428504/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Herbst%20RS,%20Soria%20JC,%20Kowanetz%20M,%20Fine%20GD,%20Hamid%20O,%20Gordon%20MS,%20et%20al.%20Predictive%20correlates%20of%20response%20to%20the%20anti-PD-L1%20antibody%20MPDL3280A%20in%20cancer%20patients.%20Nature.%202014;515(7528):563%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR20">
<span class="label">20.</span><cite>Champiat S, Ferté C, Lebel-Binay S, Eggermont A, Soria JC. Exomics and immunogenics: bridging mutational load and immune checkpoints efficacy. Oncoimmunology. 2014;3(1):e27817.
</cite> [<a href="https://doi.org/10.4161/onci.27817" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3937193/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24605269/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Champiat%20S,%20Fert%C3%A9%20C,%20Lebel-Binay%20S,%20Eggermont%20A,%20Soria%20JC.%20Exomics%20and%20immunogenics:%20bridging%20mutational%20load%20and%20immune%20checkpoints%20efficacy.%20Oncoimmunology.%202014;3(1):e27817." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR21">
<span class="label">21.</span><cite>Taube JM, Klein A, Brahmer JR, Xu H, Pan X, Kim JH, et al. Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy. Clin Cancer Res. 2014;20(19):5064–74.
</cite> [<a href="https://doi.org/10.1158/1078-0432.CCR-13-3271" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4185001/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24714771/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Taube%20JM,%20Klein%20A,%20Brahmer%20JR,%20Xu%20H,%20Pan%20X,%20Kim%20JH,%20et%20al.%20Association%20of%20PD-1,%20PD-1%20ligands,%20and%20other%20features%20of%20the%20tumor%20immune%20microenvironment%20with%20response%20to%20anti-PD-1%20therapy.%20Clin%20Cancer%20Res.%202014;20(19):5064%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR22">
<span class="label">22.</span><cite>Balachandran VP, Gonen M, Smith JJ, DeMatteo RP. Nomograms in oncology: more than meets the eye. Lancet Oncol. 2015;16(4):e173-180.
</cite> [<a href="https://doi.org/10.1016/S1470-2045(14)71116-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4465353/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25846097/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Balachandran%20VP,%20Gonen%20M,%20Smith%20JJ,%20DeMatteo%20RP.%20Nomograms%20in%20oncology:%20more%20than%20meets%20the%20eye.%20Lancet%20Oncol.%202015;16(4):e173-180." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR23">
<span class="label">23.</span><cite>Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–47.
</cite> [<a href="https://doi.org/10.1016/j.ejca.2008.10.026" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19097774/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Eisenhauer%20EA,%20Therasse%20P,%20Bogaerts%20J,%20Schwartz%20LH,%20Sargent%20D,%20Ford%20R,%20et%20al.%20New%20response%20evaluation%20criteria%20in%20solid%20tumours:%20revised%20RECIST%20guideline%20(version%201.1).%20Eur%20J%20Cancer.%202009;45(2):228%E2%80%9347." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR24">
<span class="label">24.</span><cite>Qiu C, Wang W, Xu S, Li Y, Zhu J, Zhang Y, et al. Construction and validation of a hypoxia-related gene signature to predict the prognosis of breast cancer. BMC Cancer. 2024;24(1):402.
</cite> [<a href="https://doi.org/10.1186/s12885-024-12182-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10986118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38561760/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Qiu%20C,%20Wang%20W,%20Xu%20S,%20Li%20Y,%20Zhu%20J,%20Zhang%20Y,%20et%20al.%20Construction%20and%20validation%20of%20a%20hypoxia-related%20gene%20signature%20to%20predict%20the%20prognosis%20of%20breast%20cancer.%20BMC%20Cancer.%202024;24(1):402." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR25">
<span class="label">25.</span><cite>Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol. 2013;25(1):50–1.
</cite> [<a href="https://doi.org/10.1097/CCO.0b013e32835b651e" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/23150341/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hainaut%20P,%20Plymoth%20A.%20Targeting%20the%20hallmarks%20of%20cancer:%20towards%20a%20rational%20approach%20to%20next-generation%20cancer%20therapy.%20Curr%20Opin%20Oncol.%202013;25(1):50%E2%80%931." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR26">
<span class="label">26.</span><cite>Balkwill F, Mantovani A. Inflammation and cancer: back to Virchow? Lancet. 2001;357(9255):539–45.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(00)04046-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11229684/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Balkwill%20F,%20Mantovani%20A.%20Inflammation%20and%20cancer:%20back%20to%20Virchow?%20Lancet.%202001;357(9255):539%E2%80%9345." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR27">
<span class="label">27.</span><cite>Zhang N, Jiang J, Tang S, Sun G. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. Int Immunopharmacol. 2020;85:106677.
</cite> [<a href="https://doi.org/10.1016/j.intimp.2020.106677" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32531712/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Zhang%20N,%20Jiang%20J,%20Tang%20S,%20Sun%20G.%20Predictive%20value%20of%20neutrophil-lymphocyte%20ratio%20and%20platelet-lymphocyte%20ratio%20in%20non-small%20cell%20lung%20cancer%20patients%20treated%20with%20immune%20checkpoint%20inhibitors:%20a%20meta-analysis.%20Int%20Immunopharmacol.%202020;85:106677." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR28">
<span class="label">28.</span><cite>Xie X, Liu J, Yang H, Chen H, Zhou S, Lin H, et al. Prognostic value of baseline neutrophil-to-lymphocyte ratio in outcome of immune checkpoint inhibitors. Cancer Invest. 2019;37(6):265–74.
</cite> [<a href="https://doi.org/10.1080/07357907.2019.1639057" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31304800/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Xie%20X,%20Liu%20J,%20Yang%20H,%20Chen%20H,%20Zhou%20S,%20Lin%20H,%20et%20al.%20Prognostic%20value%20of%20baseline%20neutrophil-to-lymphocyte%20ratio%20in%20outcome%20of%20immune%20checkpoint%20inhibitors.%20Cancer%20Invest.%202019;37(6):265%E2%80%9374." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR29">
<span class="label">29.</span><cite>Jin J, Yang L, Liu D, Li W. Association of the neutrophil to lymphocyte ratio and clinical outcomes in patients with lung cancer receiving immunotherapy: a meta-analysis. BMJ Open. 2020;10(6): e035031.
</cite> [<a href="https://doi.org/10.1136/bmjopen-2019-035031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7282333/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32499266/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Jin%20J,%20Yang%20L,%20Liu%20D,%20Li%20W.%20Association%20of%20the%20neutrophil%20to%20lymphocyte%20ratio%20and%20clinical%20outcomes%20in%20patients%20with%20lung%20cancer%20receiving%20immunotherapy:%20a%20meta-analysis.%20BMJ%20Open.%202020;10(6):%20e035031." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR30">
<span class="label">30.</span><cite>Kawachi H, Tamiya M, Tamiya A, Ishii S, Hirano K, Matsumoto H, et al. Association between metastatic sites and first-line pembrolizumab treatment outcome for advanced non-small cell lung cancer with high PD-L1 expression: a retrospective multicenter cohort study. Invest New Drugs. 2020;38(1):211–8.
</cite> [<a href="https://doi.org/10.1007/s10637-019-00882-5" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31784866/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kawachi%20H,%20Tamiya%20M,%20Tamiya%20A,%20Ishii%20S,%20Hirano%20K,%20Matsumoto%20H,%20et%20al.%20Association%20between%20metastatic%20sites%20and%20first-line%20pembrolizumab%20treatment%20outcome%20for%20advanced%20non-small%20cell%20lung%20cancer%20with%20high%20PD-L1%20expression:%20a%20retrospective%20multicenter%20cohort%20study.%20Invest%20New%20Drugs.%202020;38(1):211%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR31">
<span class="label">31.</span><cite>Adachi Y, Tamiya A, Taniguchi Y, Enomoto T, Azuma K, Kouno S, et al. Predictive factors for progression-free survival in non-small cell lung cancer patients receiving nivolumab based on performance status. Cancer Med. 2020;9(4):1383–91.
</cite> [<a href="https://doi.org/10.1002/cam4.2807" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7013052/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31880861/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Adachi%20Y,%20Tamiya%20A,%20Taniguchi%20Y,%20Enomoto%20T,%20Azuma%20K,%20Kouno%20S,%20et%20al.%20Predictive%20factors%20for%20progression-free%20survival%20in%20non-small%20cell%20lung%20cancer%20patients%20receiving%20nivolumab%20based%20on%20performance%20status.%20Cancer%20Med.%202020;9(4):1383%E2%80%9391." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR32">
<span class="label">32.</span><cite>Grove CS, Lee YC. Vascular endothelial growth factor: the key mediator in pleural effusion formation. Curr Opin Pulm Med. 2002;8(4):294–301.
</cite> [<a href="https://doi.org/10.1097/00063198-200207000-00009" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12055392/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Grove%20CS,%20Lee%20YC.%20Vascular%20endothelial%20growth%20factor:%20the%20key%20mediator%20in%20pleural%20effusion%20formation.%20Curr%20Opin%20Pulm%20Med.%202002;8(4):294%E2%80%93301." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR33">
<span class="label">33.</span><cite>Hegde PS, Wallin JJ, Mancao C. Predictive markers of anti-VEGF and emerging role of angiogenesis inhibitors as immunotherapeutics. Semin Cancer Biol. 2018;52(Pt 2):117–24.
</cite> [<a href="https://doi.org/10.1016/j.semcancer.2017.12.002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29229461/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hegde%20PS,%20Wallin%20JJ,%20Mancao%20C.%20Predictive%20markers%20of%20anti-VEGF%20and%20emerging%20role%20of%20angiogenesis%20inhibitors%20as%20immunotherapeutics.%20Semin%20Cancer%20Biol.%202018;52(Pt%202):117%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR34">
<span class="label">34.</span><cite>Khan KA, Kerbel RS. Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa. Nat Rev Clin Oncol. 2018;15(5):310–24.
</cite> [<a href="https://doi.org/10.1038/nrclinonc.2018.9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29434333/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Khan%20KA,%20Kerbel%20RS.%20Improving%20immunotherapy%20outcomes%20with%20anti-angiogenic%20treatments%20and%20vice%20versa.%20Nat%20Rev%20Clin%20Oncol.%202018;15(5):310%E2%80%9324." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR35">
<span class="label">35.</span><cite>Kang DH, Chung C, Kim JO, Jung SS, Park HS, Park DI, et al. Pleural or pericardial metastasis: a significant factor affecting efficacy and adverse events in lung cancer patients treated with PD-1/PD-L1 inhibitors. Thorac Cancer. 2018;9(11):1500–8.
</cite> [<a href="https://doi.org/10.1111/1759-7714.12877" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6209802/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/30253080/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Kang%20DH,%20Chung%20C,%20Kim%20JO,%20Jung%20SS,%20Park%20HS,%20Park%20DI,%20et%20al.%20Pleural%20or%20pericardial%20metastasis:%20a%20significant%20factor%20affecting%20efficacy%20and%20adverse%20events%20in%20lung%20cancer%20patients%20treated%20with%20PD-1/PD-L1%20inhibitors.%20Thorac%20Cancer.%202018;9(11):1500%E2%80%938." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR36">
<span class="label">36.</span><cite>Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–49.
</cite> [<a href="https://doi.org/10.1200/JCO.21.00174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8280089/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33872070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Reck%20M,%20Rodr%C3%ADguez-Abreu%20D,%20Robinson%20AG,%20Hui%20R,%20Cs%C5%91szi%20T,%20F%C3%BCl%C3%B6p%20A,%20et%20al.%20Five-year%20outcomes%20with%20pembrolizumab%20versus%20chemotherapy%20for%20metastatic%20non-small-cell%20lung%20cancer%20with%20PD-L1%20tumor%20proportion%20score%20%E2%89%A5%2050.%20J%20Clin%20Oncol.%202021;39(21):2339%E2%80%9349." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR37">
<span class="label">37.</span><cite>Borghaei H, Gettinger S, Vokes EE, Chow LQM, Burgio MA, de Castro CJ, et al. Five-year outcomes from the randomized, phase III trials CheckMate 017 and 057: nivolumab versus docetaxel in previously treated non-small-cell lung cancer. J Clin Oncol. 2021;39(7):723–33.
</cite> [<a href="https://doi.org/10.1200/JCO.20.01605" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8078445/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33449799/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Borghaei%20H,%20Gettinger%20S,%20Vokes%20EE,%20Chow%20LQM,%20Burgio%20MA,%20de%20Castro%20CJ,%20et%20al.%20Five-year%20outcomes%20from%20the%20randomized,%20phase%20III%20trials%20CheckMate%20017%20and%20057:%20nivolumab%20versus%20docetaxel%20in%20previously%20treated%20non-small-cell%20lung%20cancer.%20J%20Clin%20Oncol.%202021;39(7):723%E2%80%9333." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR38">
<span class="label">38.</span><cite>An M, Mehta A, Min BH, Heo YJ, Wright SJ, Parikh M, et al. Early immune remodeling steers clinical response to first-line chemoimmunotherapy in advanced gastric cancer. Cancer Discov. 2024;14(5):766–85.
</cite> [<a href="https://doi.org/10.1158/2159-8290.CD-23-0857" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11061611/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/38319303/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?An%20M,%20Mehta%20A,%20Min%20BH,%20Heo%20YJ,%20Wright%20SJ,%20Parikh%20M,%20et%20al.%20Early%20immune%20remodeling%20steers%20clinical%20response%20to%20first-line%20chemoimmunotherapy%20in%20advanced%20gastric%20cancer.%20Cancer%20Discov.%202024;14(5):766%E2%80%9385." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR39">
<span class="label">39.</span><cite>Nagasaki J, Ishino T, Togashi Y. Mechanisms of resistance to immune checkpoint inhibitors. Cancer Sci. 2022;113(10):3303–12.
</cite> [<a href="https://doi.org/10.1111/cas.15497" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9530865/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35848888/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Nagasaki%20J,%20Ishino%20T,%20Togashi%20Y.%20Mechanisms%20of%20resistance%20to%20immune%20checkpoint%20inhibitors.%20Cancer%20Sci.%202022;113(10):3303%E2%80%9312." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR40">
<span class="label">40.</span><cite>Lee DJ, Lee HJ Jr, Farmer JR, Reynolds KL. Mechanisms driving immune-related adverse events in cancer patients treated with immune checkpoint inhibitors. Curr Cardiol Rep. 2021;23(8):98.
</cite> [<a href="https://doi.org/10.1007/s11886-021-01530-2" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34196833/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Lee%20DJ,%20Lee%20HJ%20Jr,%20Farmer%20JR,%20Reynolds%20KL.%20Mechanisms%20driving%20immune-related%20adverse%20events%20in%20cancer%20patients%20treated%20with%20immune%20checkpoint%20inhibitors.%20Curr%20Cardiol%20Rep.%202021;23(8):98." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR41">
<span class="label">41.</span><cite>Ghiringhelli F, Apetoh L. The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy. Expert Rev Clin Immunol. 2014;10(1):19–30.
</cite> [<a href="https://doi.org/10.1586/1744666X.2014.865520" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24308838/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Ghiringhelli%20F,%20Apetoh%20L.%20The%20interplay%20between%20the%20immune%20system%20and%20chemotherapy:%20emerging%20methods%20for%20optimizing%20therapy.%20Expert%20Rev%20Clin%20Immunol.%202014;10(1):19%E2%80%9330." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR42">
<span class="label">42.</span><cite>Akamatsu H, Murakami E, Oyanagi J, Shibaki R, Kaki T, Takase E, et al. Immune-related adverse events by immune checkpoint inhibitors significantly predict durable efficacy even in responders with advanced non-small cell lung cancer. Oncologist. 2020;25(4):e679–83.
</cite> [<a href="https://doi.org/10.1634/theoncologist.2019-0299" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7160399/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32297443/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Akamatsu%20H,%20Murakami%20E,%20Oyanagi%20J,%20Shibaki%20R,%20Kaki%20T,%20Takase%20E,%20et%20al.%20Immune-related%20adverse%20events%20by%20immune%20checkpoint%20inhibitors%20significantly%20predict%20durable%20efficacy%20even%20in%20responders%20with%20advanced%20non-small%20cell%20lung%20cancer.%20Oncologist.%202020;25(4):e679%E2%80%9383." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR43">
<span class="label">43.</span><cite>Hussaini S, Chehade R, Boldt RG, Raphael J, Blanchette P, Maleki Vareki S, et al. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - a systematic review and meta-analysis. Cancer Treat Rev. 2021;92:102134.
</cite> [<a href="https://doi.org/10.1016/j.ctrv.2020.102134" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33302134/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Hussaini%20S,%20Chehade%20R,%20Boldt%20RG,%20Raphael%20J,%20Blanchette%20P,%20Maleki%20Vareki%20S,%20et%20al.%20Association%20between%20immune-related%20side%20effects%20and%20efficacy%20and%20benefit%20of%20immune%20checkpoint%20inhibitors%20-%20a%20systematic%20review%20and%20meta-analysis.%20Cancer%20Treat%20Rev.%202021;92:102134." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR44">
<span class="label">44.</span><cite>Remon J, Reguart N, Auclin E, Besse B. Immune-related adverse events and outcomes in patients with advanced non-small cell lung cancer: a predictive marker of efficacy? J Thorac Oncol. 2019;14(6):963–7.
</cite> [<a href="https://doi.org/10.1016/j.jtho.2019.02.031" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31027971/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Remon%20J,%20Reguart%20N,%20Auclin%20E,%20Besse%20B.%20Immune-related%20adverse%20events%20and%20outcomes%20in%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer:%20a%20predictive%20marker%20of%20efficacy?%20J%20Thorac%20Oncol.%202019;14(6):963%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR45">
<span class="label">45.</span><cite>Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, et al. Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol. 2023;9(4):527–35.
</cite> [<a href="https://doi.org/10.1001/jamaoncol.2022.7711" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9936386/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/36795388/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Socinski%20MA,%20Jotte%20RM,%20Cappuzzo%20F,%20Nishio%20M,%20Mok%20TSK,%20Reck%20M,%20et%20al.%20Association%20of%20immune-related%20adverse%20events%20with%20efficacy%20of%20atezolizumab%20in%20patients%20with%20non-small%20cell%20lung%20cancer:%20pooled%20analyses%20of%20the%20phase%203%20IMpower130,%20IMpower132,%20and%20IMpower150%20randomized%20clinical%20trials.%20JAMA%20Oncol.%202023;9(4):527%E2%80%9335." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR46">
<span class="label">46.</span><cite>Teraoka S, Fujimoto D, Morimoto T, Kawachi H, Ito M, Sato Y, et al. Early immune-related adverse events and association with outcome in advanced non-small cell lung cancer patients treated with Nivolumab: a prospective cohort study. J Thorac Oncol. 2017;12(12):1798–805.
</cite> [<a href="https://doi.org/10.1016/j.jtho.2017.08.022" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28939128/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Teraoka%20S,%20Fujimoto%20D,%20Morimoto%20T,%20Kawachi%20H,%20Ito%20M,%20Sato%20Y,%20et%20al.%20Early%20immune-related%20adverse%20events%20and%20association%20with%20outcome%20in%20advanced%20non-small%20cell%20lung%20cancer%20patients%20treated%20with%20Nivolumab:%20a%20prospective%20cohort%20study.%20J%20Thorac%20Oncol.%202017;12(12):1798%E2%80%93805." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR47">
<span class="label">47.</span><cite>Fehrenbacher L, Spira A, Ballinger M, Kowanetz M, Vansteenkiste J, Mazieres J, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.
</cite> [<a href="https://doi.org/10.1016/S0140-6736(16)00587-0" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26970723/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Fehrenbacher%20L,%20Spira%20A,%20Ballinger%20M,%20Kowanetz%20M,%20Vansteenkiste%20J,%20Mazieres%20J,%20et%20al.%20Atezolizumab%20versus%20docetaxel%20for%20patients%20with%20previously%20treated%20non-small-cell%20lung%20cancer%20(POPLAR):%20a%20multicentre,%20open-label,%20phase%202%20randomised%20controlled%20trial.%20Lancet.%202016;387(10030):1837%E2%80%9346." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="CR48">
<span class="label">48.</span><cite>Noguchi S, Suminaga K, Kaki T, Kawachi H, Fukao A, Terashita S, et al. Correlation of immune-related adverse events and effects of pembrolizumab monotherapy in patients with non-small cell lung cancer. Lung Cancer (Auckl). 2020;11:53–7.
</cite> [<a href="https://doi.org/10.2147/LCTT.S254146" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7367935/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32765147/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?Noguchi%20S,%20Suminaga%20K,%20Kaki%20T,%20Kawachi%20H,%20Fukao%20A,%20Terashita%20S,%20et%20al.%20Correlation%20of%20immune-related%20adverse%20events%20and%20effects%20of%20pembrolizumab%20monotherapy%20in%20patients%20with%20non-small%20cell%20lung%20cancer.%20Lung%20Cancer%20(Auckl).%202020;11:53%E2%80%937." class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adda93_" lang="en" class="data-availability-statement"><h3 class="pmc_sec_title">Data Availability Statement</h3>
<p>The data that support the findings of this study are not openly available due to reasons of sensitivity and are available from the corresponding author upon reasonable request.</p></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from BMC Cancer are provided here courtesy of <strong>BMC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.1186/s12885-025-14559-1"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/12885_2025_Article_14559.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (4.0 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12372320/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12372320/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12372320%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12372320/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12372320/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12372320/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40841940/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12372320/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40841940/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12372320/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12372320/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="mcU6KSCyaHZpzXQYfkoUv0cxZxqmAFaQflJdIpay7mL3Zzf6SmKEuauR4vIOXTWO">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Web Policies
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            FOIA
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS Vulnerability Disclosure
        

        
    </a>


                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Help
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Accessibility
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            









    <a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            Careers
        

        
    </a>


                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NLM
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
        

        
            NIH
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            HHS
        

        
    </a>


                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            









    <a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
        

        
            USA.gov
        

        
    </a>


                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-133c6271.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-44d04358.js"></script>
    
    

    </body>
</html>
